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The majority of the reported genetic disorders in the UAE population are of 
the autosomal recessive type, which is mainly due to high rates of consanguinity 
within the UAE national population, and within a significant proportion of other 
UAE expatriate communities; such as Arabs and Pakistanis. It is estimated that more 
than 50% of all marriages among Emiratis occur between biologically related 
couples, with first cousin marriages being the highest. That could be attributed to 
sociocultural values in the region. Successful management of genetic diseases can be 
achieved by the implementation of effective preventative programs that could help 
reduce the number of new cases, and provide early diagnosis to potentially improve 
disease management. For these desired outcomes to be achieved, it is imperative to 
identify the molecular causes (i.e. disease-causing genes and mutations) of such 
disorders. Therefore, the aim of this study is to elucidate the molecular pathology and 
cellular mechanisms of a group of recessive disorders affecting Emirati and 
expatriate families in the UAE. Whole exome sequencing, together with 
homozygosity mapping and segregation analyses, were performed on the recruited 
families to elucidate the causative genes and mutations. Where necessary, 
bioinformatics in silico analyses coupled with cellular and other functional studies 
were performed to confirm pathogenicity and uncover the cellular mechanisms of the 
studied disease phenotypes. In this dissertation, I report the identification of two 
novel compound heterozygous mutations in Multiple PDZ domain (MPDZ) gene 
causing congenital hydrocephalus, and provide experimental evidence on their 
pathogenesis and mechanisms of action. In addition, I report the identification of a 






dysplasia II (DBQDII), and provide evidence on the involvement of the endoplasmic 
reticulum (ER) quality control in the cellular mechanism of several DBQDII-causing 
mutations, including, the newly identified one. Furthermore, I provide preliminary 
data on candidate genes in two families affected by suspected monogenic intellectual 
disability syndromes. Overall, this dissertation provides evidence on the 
pathogenicity of several mutations and associated cellular mechanisms. The 
outcomes of this project will likely be valuable for implementing effective preventive 
strategies at least for the extended family members of the affected individuals. 
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Title and Abstract (in Arabic) 
رات الطف طريقة تطور المرض الناتج عنت جينية وخلوية ترسخ ميكانيكية ودراسا
المتنحية الوراثية األمراض بعض الجينية في  
 صالملخ
دولة اإلمارات العربية المتحدة هي من  ومواطني بين سكانالوراثية أغلبية األمراض 
 بين مواطني ارتفاع معدل زواج األقارب من أهم أسباب ذلكو ،األمراض الوراثية المتنحية
عند  .  نسبة الزواج من األقاربمثل العرب والباكستانيين القاطنينسكان ال بعض بينو الدولة
ألولى. يعود أبناء العم من الدرجة ازواج حيث أن معظمها من  ،%05تفوق ال  مواطني الدولة
 أفضل منووقائية تعتبر تطبيق برامج توعوية  نإ في المنطقة. اجتماعيةذلك ألسباب ثقافية و
ضافة هذا باإل مثل تلك األمراض، ظهور حاالت جديدة ن تزايدللحد م ناجحةالتدبيرية ال الوسائل
 من الواجب إيجاد فإن ،مرغوب بهاج من أجل تحقيق نتائ لها. التشخيص المبكررإلى توفي
 )عن طريق تحديد الطفرات والجينات المسببة مسببات المرض على المستوى الجزيئي
لمجموعة من  المسببات الجزيئية والخلويةتحديد هو  لذلك فإن الهدف من هذه الدراسةللمرض(. 
لقد تم استخدام  .العربية المتحدة سكان دولة اإلماراتني وطالموجودة بين موا األمراض المتنحية
ضافة إلى ( باإلWhole Exome Sequencing) تقنيات حديثه جدا مثل تقنيات ال
(Homozygosity Mapping)  وSegregation Analysis) على أفراد العائالت )
 In) . الدراسات البيومعلوماتيةاألمراض د الطفرات الجينية المسببة لتلكلدراسة وإيجا المدروسة
Silico Bioinformaticsتم القيام التجارب الوظيفية( و ً تأكيد طريقة ا إلثبات ومبه أيضا
طفرتين عن إيجاد  نعلن في هذه األطروحة شف عن الميكانيكية الخلوية لها.كتطور المرض وال
 ( والمسببةMPDZ( في جين يدعى )Compound heterozygousنوع ) منن مستحدثتي
يجاد طفرة نعلن عن إ . باإلضافة لذلك،ذلك مخبرياهذا وقد تم إثبات  لدماغ،ا الستسقاء في
 Desbuquoisوالمسؤول عن مرض )( Xylosyltransferase I)مستحدثة في إنزيم يدعى 
dysplasia II ،) جين الكما ونزود أدلة عن تسبب (XYLT1 في أسباب تطور هذا المرض )
قد تكون  التينرشح أيضا في هذه الدراسة بعض الجينات في طفرات أخرى في هذا الجين. 
كما  ،( عند عائلتينIntellectual disability syndromesلعجز الذهني )لمتالزمة ا مسببة
هذه األطروحة تقدم أدلة على الطرق المختلفة لتطور  في المجمل،ونقدم األدلة التمهيدية إلثباتها. 






تطبيق طرق وقائية على األقل ألفراد العائالت الممتدة تطوير وتشخيص مثل تلك األمراض و
         للمصابين.
، استسقاء (Desbuquois dysplasia) الوراثية المتنحية، األمراض: مفاهيم البحث الرئيسية
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Chapter 1: Introduction 
1.1 United Arab Emirates: Country, Population and Demography 
The United Arab Emirates (UAE) is a federal state established on the 2nd of 
December, 1971 and is located in western Asia between 22°30' and 26°10' north 
latitude and 51° and 56°25′ east longitude, with a total area of 83,600 km². It is a 
constitutional federation consisting of seven emirates with Abu Dhabi as the largest 
emirate where the capital (Abu Dhabi City) and the city of Al Ain are located. The 
UAE is bordered by Oman from the east and south, Saudi Arabia from the west and 
the Arabian Gulf from the north and east.   
1.1.1 UAE Population and Society 
The total population of the UAE was estimated at 9.38 million people in 
2016, and is predicted to grow to 9.9 million by 2020.  The current UAE population 
is  very diverse due to the high migration rates and is ranked 7th worldwide in the net 
migration rate ("United Arab Emirates Population", 2017).  
The population of the UAE is cosmopolitan which is attributed to the 
migration from the Indian subcontinent, Asia, Baluchistan which lies southeastern-
most edge of Iran, Pakistan, Oman and  Afghanistan to the area (Quaife et al., 1994, 
p. 42). South Asians comprise (58%) of the total residents, followed by other Asians 
(17%) and western expatriates (8.5%) ("United Arab Emirates Population", 2017). 
The UAE nationals constitute around 11% of the total population ("UAE Population 






1.1.2 Consanguineous Marriages and Reproductive Health in UAE 
 The term consanguinity refers to marriage between blood relatives, the Latin 
prefix “con” means “with” and “Sanguis” means “sense of blood”, and so the term 
“consanguineous” is used to describe members who descend from the same ancestor 
("Consanguineous", 2017). Medically, it is defined as the union between a couple 
who is second cousins or closer. This union is measured by the inbreeding coefficient 
(F) which is the probability of two alleles to be identical by descent (Leutenegger et 
al., 2003), being equal or higher than 0.0156 (Bittles, 2001), that was conventionally 
performed by counting the number of meiosis from loops in pedigrees. However, a 
new method has been developed to estimate (F) by genome-wide marker maps 
(Leutenegger, Sahbatou, Gazal, Cann, & Genin, 2011). Consanguinity is still a 
preferred practice in the Arab world including UAE, exceeding 50% of all marriages 
in some populations in the Middle East (Figure 1). 
 
Figure 1:  The global rate of consanguinity (Hamamy, 2012) 






In a study conducted in selected cities in UAE between 1994 and 1995, the 
prevalence of consanguinity in UAE reached (50.0%) with inbreeding coefficient of 
0.0222 (L. I. Al-Gazali et al., 1997), while the rate of consanguinity is less than 
(0.5%) in the European population. Despite the increase of awareness of the health 
risks of consanguinity, this practice is still prevalent in most Arab countries and it is 
not even diminishing as a recent study of 600 Saudi women revealed (Warsy, Al-
Jaser, Albdass, Al-Daihan, & Alanazi, 2014). In addition, it was observed that the 
migration of communities practicing consanguinity to the western countries led to an 
incremental rise in human inbreeding research. Although there are many conflicting 
findings on the relation between consanguinity and general health such as fertility, 
mortality and morbidity, it is agreed that it is a disadvantageous practice, in addition 
to its clear link to higher rates of autosomal recessive disorders (ARDs) among 
highly consanguineous populations  (Bittles, 2001) 
1.1.3 Autosomal Recessive Disorders (ADRs) 
ARDs are diseases that run in families due to the transmission of a recessive 
allele to offspring of carrier parents and that is manifested, in the majority of cases, 
when the child is homozygous for the abnormal allele (Figure 2). ARDs are 
monogenic disorders, the latter being categorized into dominant and X-linked and 
recessive diseases. Although most monogenic disorders are rare individually, there 
are millions of people worldwide affected by monogenic disorders and hence exert a 
significant burden on population health ("World Health Organization", 2017). Highly 
inbred communities encounter high numbers of ARDs, even the occurrence of two or 
more ARDs have been often encountered within the same family in such 






causing alleles could be hidden for generations and are expressed upon 
consanguineous marriages in subsequent generations (Jaouad et al., 2009). 
 
Figure 2: Autosomal recessive pattern of inheritance. The affected child inherited 
both recessive alleles from his heterozygous parents, while the carrier children, each 
has inherited one normal allele from either parents and another mutated from the 
other. The healthy sibling, on the other hand, received two copies of the wild type 
allele from her parents (Lentz & Keats, 1993). 
The number of genes to cause ARDs is steadily rising due to recent 
discoveries and expected to reach several thousands. The number of genetic 
conditions, including ARDs, with known molecular causes currently stands above 














In a study attempted to generate whole exome variome on the Greater Middle 
East (GME) region on 1,111 distant individuals, they detected large and rare (Runs 
Of Homozygosity) (ROH) that would definitely assist in discovering more recessive 
disease-causing genes, this database could be used as a source of human variants in 
the Middle East and worldwide (Scott et al., 2016)  
Furthermore, autosomal recessive disorders comprise the majority of many 
diseases. For example, intellectual disability (ID) which exists in around 1% of the 
world population is mostly inherited in an autosomal recessive pattern. In a study 
which combined WES and homozygosity mapping, they were able to identify new 
candidate genes implicated in autosomal recessive intellectual disability (ARID) 
supported with transcriptional functional analyses (Harripaul et al., 2017)  
On the other hand, regardless of the genotype-phenotype correlation and 
pattern of inheritance in diseases, recessive inheritance identified in dominant 
disorders should not be ignored as a study on Saudi families revealed. They 
described 11 recessively inherited variants in genes previously and exclusively 
implicated in dominant disorders. Intriguingly, they even observed new phenotypes 
which revealed similar phenotypes in animal models knock-outs (Monies et al., 
2017). 
1.1.4 Screening, Preventive Measures and Genetic Services 
Screening strategies for genetic disorders include premarital, pre-conceptive, 
neonatal, and population screening. The major aim behind these programs is to 
reduce their occurrence and provide tools to diagnose them and ameliorate their 
effects and possibly develop novel therapies. This could be done by promoting 






high school education and ending up with media, and that includes educating them 
about the dangers of consanguinity (Teebi, 2010). 
In UAE, the genetic services are still generally inadequate, taking place in 
few centers across UAE, consultation is provided by a small number of clinical 
geneticists, mainly providing counseling on thalassemia and sickle cell anemia as a 
premarital testing. Moreover, those centers provide newborn screening for some 
genetic condition such as phenylketonuria, congenital hypothyroidism and congenital 
adrenal hyperplasia (L. Al-Gazali, Hamamy, & Al-Arrayad, 2006). This topic was 
recently addressed in the genetic counseling workshop which took place at the 6th 
Pan Arab Human Genetics Conferences (PAHGC) held in Dubai, UAE in 2016. 
Encouraging the entities to take the responsibility in implementing counseling 
programs and centers (Nair et al., 2016). 
On one hand, the health authority in Abu Dhabi (HAAD) implemented the 
newborn screening for the critical congenital heart diseases (CCHD), which has an 
incidence of 8 per 1000 births in Abu Dhabi. This program resulted in the successful 
detection of ten newborns suffering from CCHD and that led to adopting screening 
programs on other diseases (Al Mazrouei, Moore, Ahmed, Mikula, & Martin, 2013). 
On the other hand, pre-marital and pre-conception screening tests are not of 
less importance due to the high prevalence of inherited disorders and carriers states 
in UAE. For example, carrier frequencies of hemoglobinopathies such as β-
thalassemia and sickle cell anemia corresponded to 4.56% and 2.9%, respectively 






Other congenital disorders such as congenital hypothyroidism (CH) were 
expected to be due to genetic mutations in a study that took place in Abu Dhabi from 
2011-2014. Genetic testing was performed on 10 out of 65 suspected patients and 3 
patients were found to have mutations, one with a heterozygous mutation in thyroid 
stimulating hormone receptor (TSHR) gene and two with homozygous mutations in 
thyroid peroxidase (TPO) gene (Deeb et al., 2016). 
1.2 Statement of the Problem 
Despite significant efforts and discoveries on the underlying causes of many 
monogenetic disorders in Arab countries and UAE, the rates of birth defects are still 
unacceptably high in most Arab countries. For example, in the March of Dime 2006 
report, the UAE was ranked sixth worldwide in terms of birth defects. It is believed 
that 70% of birth defects’ effects could be prevented or decreased if diagnosed before 
conception or at early stages of conception (The Catalogue for Transmission 
Genetics in Arabs (CTGA) database (www.CAGS.org.ae). As indicated previously, 
these high rates are most likely due to social tendencies as well as inadequate 
preventative programs. For every 1000 live births in most Arab countries, 70-79 are 
born with either physical or intellectual birth defects, for the UAE, 75.6 per 1000 live 
births (March of Dimes report, 2006). That was closely attributed to the common 
practice of consanguineous marriages, leading to high opportunities for combining of 
recessive disease-causing alleles. Consanguinity in UAE exceeds half of all 
marriages. Consequently, autosomal recessive disorders contribute to a high 
proportion of genetic disorders and birth defects in UAE. Given the magnitude of the 






can be potentially reduced by implementing more effective educational programs 
including preventative interventions and accurate diagnostic provisions and tools. 
According to experts in the human genetics field, the burden of genetic 
disorders in UAE could be reduced considerably by implementing more effective 
prevention programs. Genetic diseases are ranked fourth in terms of fatality in UAE. 
Craig Venter described the high rates to be unusual. He added, that only when this 
population’s genome is deciphered then changes could be made (Griffiths AJF, 
2000). 
Currently there are more than 400 genetic disorders described in UAE. 
Although this number is normal in highly consanguineous communities, it is 
considered a major public health problem in UAE. Therefore, our aim here is to 
elucidate the genetic and cellular basis of rare inherited diseases in Emirati families 
as well as UAE residents, pointing out the importance of studying those families, 
hoping to provide tools for diagnosis that can be employed for more effective genetic 
counselling and prevention programs, as well as mapping the causal genes and 
mutations to build up and add more information to the body of scientific and medical 
knowledge. 
1.3 Objectives 
• Characterize Emirati families and expatriate residents of the UAE with 
children affected by single gene disorders.  
• Perform homozygosity mapping on families affected by suspected autosomal 






homozygous regions that are common among the genomes of affected 
individuals. 
• Perform whole exome sequencing (WES) on selected affected individuals 
from these families to identify candidate causative genes and variants. 
• Conduct Sanger DNA sequencing in candidate genes on those families to 
confirm segregation of variants and narrow down or confirm the candidate 
causative mutations. 
• Perform bioinformatics, in silico and functional analyses to confirm 
pathogenicity and elucidate the pathogenesis mechanisms. 
1.4 Relevant Literature 
1.4.1 The Genetic Basics 
Genetics is the branch of science concerned with heredity. Offspring inherit 
genes from both parents, which will in turn be expressed into traits, disorders, or 
disease risks. The vast majority of our genes are located within the 23 pairs of 
chromosomes in a specific order. A copy of each of pair of chromosomes is inherited 
from each parent and therefore a copy of each gene. Moreover, genes consist of 
nucleotides linked in a very specific order. There are over 20,000 genes within the 
human genome, which is defined as the whole set of DNA including all the genes of 
an organism. DNA is made of four types of nucleotide bases (Adenine, Guanine, 
Cytosine and Thymine, generally referred to as A, G, C, and T, respectively). There 







The process of determining the complete sequence of the genome is called 
whole genome sequencing (WGS). Although, it started as a research tool, WGS is 
now employed routinely for diagnostic and therapeutic purposes. The idea of 
sequencing the whole human genome was initially introduced in 1985 and formed 
the first step towards the human genome project, launched officially in USA in 1990 
and completed in 2003 (Venter, Smith, & Adams, 2015). 
1.4.2 The Inherited Disorders 
Inherited disorders are diseases that are passed down from parents to 
offspring due to single gene mutation or chromosomal aberrations. Although most 
single gene disorders are inherited in Mendelian patterns, phenotypes are not always 
easily predicted. For example, in Gaucher disease (MIM 230800), there is no clear 
correlation between the genetic mutation and the phenotypes of the patients (Sriram, 
Martinez, McCabe, Liao, & Dipple, 2005). On the other hand, chromosomal 
aberration refers to any change in the structure (e.g, translocations, duplication and 
deletions) or number (Aneuploidy) of the chromosomes due to breaks or alterations 
in the DNA (Bender, Griggs, & Bedford, 1974). Structural aberrations are mainly 
caused following improper DNA repair, whereas numerical aberrations occur due to 
segregation errors (non-disjunction) during cell division (Janssen, van der Burg, 
Szuhai, Kops, & Medema, 2011). On the other hand, when genetic variations are 
combined with environmental factors; that would increase the risk and may lead to 
the development of multi-factorial disorders such as Schizophrenia, autism, 
depression, type 2 diabetes. These disorders are often familial but they do not follow 






threshold above which individuals would show symptoms (Fraser, 1976). (Mitchell, 
2012).  
1.4.3 Overview of the Diagnostic Approach in Genetic Conditions 
Mutation detection using DNA sequencing is becoming an essential 
component of the diagnosis of genetic diseases. It can be carried out at the prenatal, 
premarital, pre-implantation periods and used for diagnostic purposes (Cotton, 1993). 
Methods of detection of single gene mutations could be performed by direct 
sequencing of the DNA or RNA using different PCR techniques and microarrays 
(Mahdieh & Rabbani, 2013), or indirectly in linkage study analyses using Short 
tandem repeats (STRs) or single nucleotide polymorphisms (SNPs) markers. 
NGS has become an essential tool in disease gene discovery and diagnosis; it 
refers to any high-throughput, cost effective technologies. These technologies can be 
applied in WGS, WES, transcriptome sequencing, chromatin immunoprecipitation 
(ChIP) sequencing, epigenome characterization, etc. Although mutations in exons 
cover 85% of the Mendelian disorders, a significant number of potentially harmful 
variants, within non-coding regions for example, could be left undetected by WES, 
hence, WGS is favorable in some cases, especially when WES fails to reveal the 
causative mutation (Mahdieh & Rabbani, 2013). Additionally, there are several other 
approaches to identify mutations by direct DNA re-sequencing.  
Transcriptome sequencing on the other hand, provides insights on the 
expression levels of genes in cells in a real-time fashion by generating libraries 
through fragmentation, ligation, and sequencing, also called RNA sequencing, being 






Moreover, ChIP sequencing allows the fragmentation and 
immunoprecipitation of DNA-associated proteins and sequencing the DNA after 
hybridizing it on a chip (ChIP-Chip microarray) (de Magalhaes, Finch, & Janssens, 
2010).  
 On the other hand, chromosomal abnormalities can be identified by 
cytogenetic methods using conventional karyotyping, fluorescent in situ 
hybridization (FISH), comparative genomic hybridization (CGH) or microarrays 
(Riegel, 2014). The overall approach of diagnosis also involves physical 
examination, biochemical or cytogenetic testing in some diseases.  
1.4.3.1 Physical Examination 
The main objective of medical geneticists is to describe the cause of birth 
defects or developmental abnormalities in children or adults. Although it seems 
similar to the general medical examination, physical examination however in these 
cases aims to closely examine any deviations in development from normal. One of 
the major factors which could help in diagnosis is the occurrence of a phenotype in 
family history, either in live or still births. Moreover, the presence of dysmorphic 
features, intellectual disabilities and developmental delay are highly suggestive of 
genetic disorders (Best, Rosser, & Bajaj, 2017). Despite the fact that most genetic 
disorders are presented during childhood, such disorders should not be overlooked if 
they show up in adulthood ("Genetic Alliance; The New York-Mid-Atlantic 






1.4.3.2 Biochemical Testing 
Changes in protein levels and/or activity may be due to a mutation in the 
gene’s DNA sequence. In cases of biochemical enzymes, this often results in a 
genetic disorder belonging to the so called “inborn errors of metabolism”. This group 
of genetic disorders include fatty acid oxidation disorders, organic acidurias, 
aminoacidopathies and others (Schiff, 2017). Measuring body fluids’ changes of 
such enzymes and/or their metabolites may help in their diagnosis (Sandlers, 2017). 
Currently, tandem mass spectrometry allows for measuring more than 20 
biochemical genetic disorders by looking at the levels of their metabolites. However, 
expanded newborn screening tests have raised a major concern of false positive 
results due to child-parental anxiety rather than laboratory errors. These concerns can 
be overcome by educating parents prior to testing in order to benefit from the 
positive impact of such tests on the well-being of the affected infants (Holtzman, 
2004). 
1.4.3.3 Cytogenetics 
Cytogenetics is a field of genetics concerned with the analysis of the numbers 
and structures of chromosomes and consequences related to their abnormalities. 
Chromosomes for cytogenetic testing could be obtained from several sources such as 
peripheral blood, fetal blood, oocytes, spermatozoa, and others. Assessment of the 
integrity of chromosomes is carried out through karyotyping. Since 1960s diagnostic 
cytogenetics has evolved, allowing DNA and RNA probes to recognize genetic 
sequences using different techniques (Trask, 2002). Cytogenetic microarrays are 
becoming crucial tools in clinical use for the diagnosis of chromosomal 






variants (CNVs) are determined in patients compared to controls. Although 
microarray is a robust technique for CNVs, it should not  always be the first option 
due to the long turn-around time. For example, karyotyping is more useful in 
aneuploidies, and fluorescent in situ hybridization technique (FISH) is more 
appropriate in diagnosing a well-described syndromes such as Williams and De 
George syndromes (Manning & Hudgins, 2010). 
1.4.3.4 Molecular Analysis 
The human diploid cell is composed of nearly 6 billion base pairs making up 
the 23 pairs of chromosomes, in addition to the mitochondrial genome which codes 
for 37 genes only. Genomic variation exists among individuals and population 
causing differences at the DNA level that can be inherited among offspring. If these 
variations result in a disordered state, they are termed ‘mutations’. Whereas, non-
deleterious variations are termed ‘polymorphisms’ (Javed, Huang, & Bombard, 
1995).  
Molecular analysis is an approach which is concerned with the analysis of 
DNA, RNA or proteins in some cases. There are direct and indirect molecular 
methods to this approach. The direct method is most applicable when the causative 
gene of a particular disease is known. Hemoglobinopathies are the best examples of 
such diseases. Direct DNA sequencing and the use of restriction enzyme digestion 
are examples on direct analyses. For example, restriction fragment length 
polymorphism (RFLP) detects differences between DNA sequences after applying 
restriction endonucleases, followed by hybridizing the fragments with labeled probe 
and running it in gel electrophoresis (Lander & Botstein, 1989). Indirect methods, on 






causes, in such cases linkage studies using polymorphic DNA markers closely 
related to the disease-causing genes such as short tandem repeats (STRs) or SNPs, 
are the most appropriate choices  (Javed et al., 1995). 
1.4.3.5 Next Generation Sequencing (NGS) 
DNA sequencing had undergone unprecedented rapid and significant 
developments over the last few years allowing the human genome, for example, to be 
sequenced in a few days for around USD 1000 (Petersen, Fredrich, Hoeppner, 
Ellinghaus, & Franke, 2017). Efforts to develop methods for DNA sequencing 
started in the early 1970s with Gilbert and Maxam in 1973 using wandering-spot 
analysis (Maxam & Gilbert, 1980).  A few years later Fredrick Sanger developed a 
novel methodology using chain-terminating dideoxynucleotides, now known as 
Sanger Sequencing. Although it was used for the human genome sequencing project, 
due to its long turn-around time this method is unsuitable for large-scale sequencing 
projects that involves the sequencing of whole genomes of large number of 
individuals. Therefore, efforts to speed up sequencing at reduced costs were intensive 
globally which resulted in the development of the first next generation sequencing 
instrument around the mid-2000s (Venter et al., 2015).  
The next step-forward in NGS was the introduction of enrichment methods 
by designing probes that could select DNA fragments, such as extracting exons in 
whole exome sequencing (WES) (Petersen et al., 2017). 
All the different types of NGS platforms do sequencing to millions of DNA 
fragments in parallel. Moreover, these fragments are sequenced multiple times to 
reach high depth sequencing for more reliable data in a short period of time. 






comprehensive bioinformatics expertise to analyze and interpret the NGS data. In 
addition, there is a need for the use of high storage capacity computers and 
sophisticated IT set ups (Behjati & Tarpey, 2013). 
1.4.4 Tools for Genetic Analysis 
1.4.4.1 Bioinformatics and Computational Analysis 
Genomic technologies generate remarkable amounts of genetic data that 
requires soft-wares and tools for their analysis and storage. Bioinformatics is the 
branch involving both computing and biology concerned with this process. For 
example, scientists use computational analysis of genes to identify their functions for 
diagnostic and sometimes therapeutic purposes. In the case of NGS, bioinformatics 
tools are employed for mutation prediction, gene expression, gene regulation and 
many other applications (Lindblom & Robinson, 2011). 
Computational analyses are applied in multi-disciplinary fields in genetics, 
for example, aligning DNA or amino acid sequences among different species is 
performed daily using Basic Local Alignment Search Tool (BLAST) algorithms 
(Benson, Karsch-Mizrachi, Lipman, Ostell, & Wheeler, 2008). Additionally, genome 
wide associations studies (GWAS) performed to identify variants as risk factors 
predictors associated with different diseases, especially multifactorial conditions, 
have used robust bioinformatics tools to integrate data from different data bases such 
as Human Genome Research institute (NHGRI) and SNAP (SNP Annotation and 






1.4.4.2 Whole Exome Sequencing (WES) 
WES is a robust, reproducible method that sequences most targeted protein-
coding regions on the DNA to identify changes in the human genome in patients with 
genetic disorders. Several WES platforms have been developed, in principle, 
solution-based WES involves DNA shearing, labelling and hybridizing to 
oligonucleotide probes bound to magnetic beads, washing away the unbound, 
followed by PCR for enrichment and sequencing. The same applies on array-based 
methods except for capturing probes on a microarray chip (Warr et al., 2015).  
The first story of success of using WES for the diagnosis of single gene 
disorders was back in 2010 with three individuals suffering from Miller syndrome 
(Ng et al., 2010). Henceforth, WES has been extensively applied to detect novel 
mutations (Worthey et al., 2011) and currently employed in routine use in most 
developed molecular diagnostic genetic laboratories (Valencia et al., 2015). 
WES is also useful in the diagnosis of early, incomplete spectrum of 
symptoms and in prenatal diagnosis (Iglesias et al., 2014) allowing for a confirmed 
diagnosis and prognosis, finding better treatment and avoiding unnecessary invasive 
procedures to the patients  (Warr et al., 2015). 
Despite the fact that whole genome sequencing is becoming more affordable 
due to the drop in sequencing costs, WES is still the cheaper choice, so it remains a 
suitable tool when combined with powerful statistical approaches. Additionally, 
whole genome sequencing is hampered by the need of huge storing and data analysis 
technologies that have not accelerated as sequencing technologies have (Sboner, Mu, 






WES has been lately combined with other strategies such as linkage analysis 
and homozygosity mapping in the filtration process to identify novel variants in 
consanguineous families affected by autosomal recessive disorders (T. Guo et al., 
2017), among which, compound heterozygous mutations and copy number variations 
(CNVs) are common. However, WES remains a challenging procedure to identify 
CNVs, making other suitable analytical methods needed such as array platforms and 
quantitative real-time PCR (qPCR) (Li & Olivier, 2013). 
1.4.4.3 Sanger Sequencing 
Sanger method was developed by Fredrick Sanger in the late 1970 and is a 
procedure to determine the DNA sequence using (DNA polymerase I) which 
incorporates radiolabelled triphosphates into the 3’ end of a primer polynucleotide 
and extended complementarily in four separate reactions, synthesis would proceed 
until the incorporation of a di-deoxyribotriphosphate leading to a termination of the 
reaction. Later in 1986 an automated Sanger sequencing method was developed by 
attaching different colored fluorophores to the four nucleotide bases and the mixture 
electrophoresed in a single gel tube. Subsequently, the fluorescent bands were 
analyzed by a computer’s software (Figure 4) (Smith et al., 1986). In 1987 Applied 
Biosystems introduced the first machine called AB370, detecting 600 bases read 
length. In 1995, the model AB3730xl reached a read length of 900 bases. In 1998, 







Figure 4: Sanger sequencing by chain-terminating di-deoxynucleotides 
(http://www.vce.bioninja.com.au/) 
1.4.4.4 Homozygosity Mapping 
It is well established that consanguinity increases the chances of acquiring 
genetic disorders due to the increase in the percentage of the genome that is identical 
by descent. Relatedness can be measured by the inbreeding coefficient (F), ranging 
from third cousin to double first cousin marriages (F=>0.4-12.5%). Disease-causing 
genes often reside in blocks of homozygosities passed to progeny (Alkuraya, 2010), 
and in the case of rare autosomal disorders, the probability of having homozygous 
mutations is higher than the state of compound heterozygous mutations (Aldahmesh 
et al., 2009). Therefore, it is much easier to scan disease-causing genes within the 
homozygous regions among consanguineous families than in outbred ones, where 







Homozygosity mapping is a robust technique which identifies homozygous 
regions on the chromosomes using SNP genotyping arrays. For example, the 
genome-wide human SNP array 6.0 can detect more than 900,000 SNPs. For 
homozygoisty mapping, the genomic DNA is digested using restriction enzymes 
(REs) and ligated to adaptors that can be recognized by generic primers for 
amplification. Subsequently, all amplicons will be fragmented, labelled, and then 
hybridized to the microarray chip (Figure 5). 
 
Figure 5: Illustration of the human genome wide SNP genotyping array 6.0 
(http://www.seoulin.co.kr/) 
Homozygosity mapping is considered a powerful technique in the 
identification of heterogeneous ARDs in highly consanguineous populations. For 
example, in seven Saudi families suffering from Bardet-Biedl syndrome with poor 
genotypic-phenotypic correlation where conventional direct DNA sequencing of the 






novel deep intronic regions which resulted in splice-site mutations (Abu Safieh et al., 
2010). 
1.4.4.5 Variants Filtering Techniques 
The vast amount of data generated from WES requires significant 
bioinformatics analyses in order to identify the causative mutations and genes. 
Filtration techniques can be automated or manually performed, but dependence on 
automation alone could lead to finding some false positives or elimination of relevant 
candidate variants (Jalali Sefid Dashti & Gamieldien, 2017). 
Filtration of variants highly depends on bioinformatics tools to predict their 
effect on the protein function. However, analysts should carefully estimate the 
validity of such predictions, recent studies have shown that half the ‘predicted’ 
deleterious variants turned out to be neutral (Miosge et al., 2015). It is thus advisable, 
according to published guidelines, to combine several protein prediction tools during 
filtration such as SIFT (sorting intolerant from tolerant), PolyPhen (Polymorphism 
Phenotyping) (Sim et al., 2012), (Adzhubei et al., 2010), Mutation Taster, FATHMM 
(Functional Analysis Through Hidden Markov Models), and others to increase the 
prediction specificity (Jalali Sefid Dashti & Gamieldien, 2017). Additional tools for 
analyzing domains of translated proteins and the positioning of the variants within is 
a supportive step to be performed in the filtering pipeline. One of the classical, 
diagnostic and powerful tools is the InterProScan database (www.ebi. 
Ac.uk/interpro/search/sequence-search). 
During filtration it is advisable to look into Ensembl transcripts rather than 
reference sequences (RefSeq), since it was shown by McCarthy and his colleagues 






there was 44% agreement in annotations between RefSeq and Ensembl transcripts 
leading to the dismissal of interesting and perhaps relevant variants (McCarthy et al., 
2014). 
Potential consequences of variants such as missense, splice-site and nonsense 
are highly considerable compared to the intronic and synonymous ones assuming 
they have no functional impact. Additionally, conservation of the sequenced variants 
among species as well as the population frequencies of filtered variants are 
paramount criteria because the rarity of the variant has a greater attribution to the 
disease than the recurrently occurring ones, the most frequently studied is the minor 
allelic frequency (MAF) which is favorable to be the starting point in any filtering 
study. Allelic frequency data can be retrieved from multiple sources, some of the 
most widely used are from Ensembl (http://asia.ensembl.org/), ExAC browsers 
(Exome Aggregation Consortium) (http://exac.broadinstitute.org/), and the Exome 
Variant Server (evs.gs.washington.edu/). 
Furthermore, candidate genes can be filtered based on relevant clinical 
phenotypes assisted by robust databases like OMIM (Online Mendelian Inheritance 
in Man) (http://www.omim.org/) and Gene Distiller (www. Genedistiller.org). The 
Human Gene Mutation Database (HGMD) also simplifies filtration through 
collecting all the published mutations and related inherited diseases (http://www. 
hgmd.org). 
As stated earlier, there is no single and unified pipeline to use for filtration 
since all have limitations and drawbacks. Generally, if a variant achieves most of the 
pipeline criteria, then it is expected to have genotype-phenotype correlation, however 










Figure 6: Designed guide for the filtering and prioritizing of variants 
 
1.4.5 Major Cellular Mechanisms of Genetic Diseases 
1.4.5.1 Loss of Function versus Gain of Function 
 Mutations in genes could either lead to losing the native function of the 
protein (loss-of-function, LoF) or acquiring a new function to the protein (gain-of-






catalytic domain (LoF) such as mutations in fumarate hydratase enzyme, 
predisposing individuals to multiple cutaneous and uterine leiomyomatosis (MCUL) 
(Alam, Olpin, & Leigh, 2005), or they could lead to gaining a new enzymatic activity 
like mutations in isocitrate dehydrogenase in human gliomas (Guo, Pirozzi, Lopez, & 
Yan, 2011). On the other hand, different mutations on the same gene could lead to 
different phenotypes, for example in FGFR1 gene, LoF mutations result in 
craniosynostosis, whereas GoF mutations cause Kallmann syndrome. There are some 
features that could distinguish LoF and GoF mutations with statistical accuracy 
levels of around 70%. Jung S. and his colleagues found that the mutation type, the 
substituted allele, the functional effect of the mutation and the domain affected are 
among the features determining LoFs and GoFs (Jung, Lee, Kim, & Nam, 2015).  
Since most ARDs, the subject of this dissertation, are caused by LoF mutations, the 
following sections will deal with the major LoF mechanisms. 
1.4.5.2 Nonesense Mediated Decay (NMD) and Destabilization of the mRNA 
 NMD refers to the degradation of mRNA due to carrying a pre-mature stop 
codon mutation. Decay occurs after introns splicing, in their way to produce the 
mature mRNA. Naturally, around 30% of mRNA splice variants undergo NMD, 
splicing occurs on consensus sequences by splicesomes. Some studies attributed the 
physiological levels of mRNA to NMD processes, that’s why NMD is a crucial 
mechanism in the nervous system to maintain the levels of gene expression in cells 
that would otherwise lead to neurological disorders (da Costa, Menezes, & Romao, 
2017).  
NMD is essential in preventing the dominant negative effects of the non-






growing evidence that NMD could alternatively be harmful due to the lack of protein 
synthesis which might retain some residual activity. In some diseases the NMD 
mechanism gives milder phenotypes due to haploinsufficiency such as mutations in 
SOX10 gene in Waardinburg disease or in LDLR causing familial 
hypercholesterolemia, while in other cases, the synthesis of the mutated protein leads 
to dominant negative effect like nonsense mutations in SOX10 gene leading to severe 
phenotypes (Inoue et al., 2007). 
1.4.5.3 Protein Mis-folding, Mis-localization and Prevention of Posttranslational 
Modifications 
 After their synthesis on ribosomes, proteins need to fold and often must get 
modified and assemble into complexes before they can perform their biological 
function, and secretory pathway targeted proteins are no exception. The endoplasmic 
reticulum (ER) is the entry point organelle of the secretory pathway and is 
responsible for many cellular processes including protein folding, assembly and 
secretion. About one third of translated proteins are targeted to the ER (Powers & 
Walter, 1997), where their final destination is determined to different post-ER 
compartments via a signal peptide of 20-30 amino acids in length (Johnson & van 
Waes, 1999). They also get folded during translational process, but the major folding 
occurs in the ER lumen where the signal peptide is cleaved influencing proper 
folding. Post-translational modifications such as disulfide bonds, acetylation, 
glycosylation, and biotinylation are crucial for folding (Helenius & Aebi, 2001). 
Additionally, molecular chaperones like the heat shock proteins, calnexin, and thiol-
oxidoreductases are the gate-keepers for protein folding, they function by lowering 
the free-energy barriers and the formation of aberrant molecules (Nishikawa, 






If a protein is misfolded, it will be either; refolded, degraded or sequestered. 
Misfolded proteins are recognized by different ER molecular chaperones that help 
their retention, targeting them for further folding. Folding becomes inefficient when 
the total protein concentrations reach high amounts, taking several hours (Kleizen & 
Braakman, 2004). The ER quality control machinery will tag them for degradation 
via the ubiquitin proteasome system (UPS). For most proteins, the proper three- 
dimensional protein structure is determined by its primary sequence. Thus, mutations 
in the amino acid sequence might cause inappropriate folding pathways, leading to 
the formation of misfolded proteins that will be often returned to the cytoplasm to be 
degraded (Figure 7). Impairments in such quality control systems could lead to 
aggregation of misfolded proteins in cells as amyloid-like structures, such as the 
cases in neurodegenerative disorders (Chaudhuri & Paul, 2006). 
 






 On the other hand, sequestration is important to contain toxic proteins away 
from the cellular environment and to enhance asymmetric inheritance of the damaged 
proteins (Sontag, Samant, & Frydman, 2017). There are multiple mechanisms in 
protein mis-folding, such as loss of function mutations as in cystic fibrosis, rendering 
the proteins unstable and prone to degradation, and in α1-antitrypsin deficiency, the 
protein is continuously degraded by UPS, thus its deficiency in its specific site 
causes the disease to occur. On the other hand, Alzheimer’s disease occurs by a gain-
of-function mechanism that results from accumulating fibrillary amyloid deposits 
(Chaudhuri & Paul, 2006). 
 When proteins are fully synthesized and folded they should traffic and get 
targeted to their final destination either inside the cellular organelles or 
extracellularly where they perform their proper function. Mislocaliztion could be 
attributed to loss of localization signals, for example loss of nuclear signal in sex 
determining region Y protein (SRY) is responsible for Swyer syndrome (McLane & 
Corbett, 2009). 
 Others could be due to aberrant folding of proteins. For example, in Robinow 
syndrome all missense mutations had been responsible for the loss of function in the 
frizzled-like cysteine rich domain and kringle domain of one of the tyrosine kinase 
receptor members (ROR2) leading to misfolding and retention in the ER (Ali et al., 
2007). Additionally, defects in cargo proteins could as well be a reason for 
mislocalization, as in rhizomelic chondrodysplasia punctata type 1, resulting from a 
mutation in PEX7 gene which encodes peroxisomal matrix import receptor 






1.4.5.4 Loss of Active Site or Significant Functional Residue 
 Amino acid sequences of enzymes that are involved in the catalytic domain 
or in the substrate binding pockets, or can at least support the configuration of the 
active site are highly conserved in proteins. Mutations in such locations could lead to 
either reduced or complete loss of their function (Porter, Bartlett, & Thornton, 2004). 
For example, certain mutations in phenylalanine hydroxylase causing 
phenylketonuria occur at the catalytic sites, inducing structural changes in the active 
domain causing PAH enzyme deficiency (Gersting et al., 2008). 
 Moreover, mutations affecting essential domains of proteins might affect 
their stability and function. For example, missense mutations occurring at domains 
16–17 of Filamin A gene (FLNA) known to cause Larsen syndrome and 
Frontometaphyseal dysplasia were studied by combining crystallography and 
simulation techniques on the protein’s structure, they found that mutations in those 
domains converted its structure from compact to elongated causing destabilization of 
the protein (Seppala et al., 2017) 
1.4.5.5 Disruption of Gene Expression 
 Intronic mutations could affect the regulatory sites of a gene and hence, 
disrupt its expression either by introducing or eliminating an enhancer’s or a 
suppressor’s activity. Moreover, mutations introducing cryptic splice-sites could alter 
mRNA expression by affecting its stability, by deleting or inserting new regulatory 
elements or generating a truncated protein, for example, the decreased levels of 
mRNA and protein expressions of the myotonin-protein kinase gene have been 






of alternative splice-variants could cause a disease state if the gene is expressed in an 
improper tissue or developmental stage (Faustino & Cooper, 2003).  
Furthermore, point mutations affecting RNA polymerase binding sites, or the 
translation-initiation sites, would potentially alter gene expression in tissues 
(Griffiths AJF, 2000). 
1.5 Rationale for this Study 
Congenital and genetic disorders are responsible for the majority of morbidity 
and mortality in UAE and the Arab world due to high consanguinity rates. This 
burden is increased due to the lack of preventative health measures. In addition, in 
single gene disorders, which have high prevalence in such communities, there isn’t 
always a direct and obvious correlation between genotypes and phenotypes. 
Therefore, studying the molecular and cellular functions through experimental 
approaches and Bioinformatics is crucial to elucidate the causal factors in some 
inherited diseases. Designing correct experiments, under which rational hypotheses 
stand, as well as interpretation of their results could provide accurate methods in 
identifying novel mutations or in discovering novel genes, consequently expanding 
the genotypic spectrum of genetic diseases and elucidate their pathogenesis. These 
findings could have a crucial impact on having accurate diagnostic tools, 
development of effective prevention programs and possibly improving management 






1.6 Potential Contributions and Limitations of the Study 
1.6.1 Limitations 
 Blood samples as well as fibroblasts were obtained, when possible, during the 
field work. Nevertheless, there were some difficulties in getting samples from 
some families either due to inaccessibility of the relevant tissue such as in the 
case of neuronal cells or due to non-collaborating members from the affected 
family. Therefore, mammalian expression plasmid constructs were developed 
and expressed in cultured cell lines as an alternative, in an attempt to evaluate 
the potential effects of the identified variants.  
 Lack of treatment options for most genetics conditions raised a challenge 
because parents of affected children often feel angry and/or frustrated in such 
cases and some of them therefore might be unwilling to fully cooperate.  
 In WES analysis, data often contain variants of uncertain significance (VUS), 
these variants cannot be neglected but require significant efforts to provide 
evidence of their pathogenicity or not. For example, in a case of intronic VUS in 
FTO gene (Fat mass and Obesity-associated protein) detected by GWAS, the 
variant was erroneously thought to affect FTO gene regulation, but turned out to 
affect distantly IRX3 gene (Iroquois-class homeodomain protein) (Smemo et al., 
2014). 
 During the filtration process of the WES data, regions outside the protein coding 
and splice sites sequences could not be evaluated despite their importance in 
regulating gene expression, although not a general feature. 
 Gene discovery sometimes requires acceptable sample size of affected 






phenotype in order to increase the power of the study. Unfortunately, it was not 
always feasible to find such criteria in multiple unconnected families due to the 
rarity of the studied disorders.  
 The studied families exhibit variable phenotypes, which was due to the nature of 
the families that were evaluated at Tawam Genetics unit. This unit is the major 
referral genetics center in UAE and supports patients with all kinds of genetic 
conditions from various parts of the country as well as the expatriate 
populations. 
1.6.2 Contributions 
 The advent of novel mutations presented in the current study is important to 
comprehend the pathogenesis and mechanisms by which the studied genetic 
disorders occur. In addition to its contribution to the diagnostic approach for 
patients affected with similar disorders, and that includes different categories, 
such as pre-conception, prenatal, neonatal, as well as late onset of the diseases in 
adult life. 
 Exploiting molecular approaches to identify novel candidate genes responsible 
for monogenic disorders and if proved, to determine the mechanisms by which 
they cause the phenotypes. 
 Defining strategies for population screening who are highly at risk, such as 
communities with highly in-bred families who would most probably host large 
numbers of carriers of genetic mutations. This category can be screened for 
known mutations and identified as carriers, with aim to limit further 
implications, especially among members of their extended families who might 






 Genetic research contributes to genetic counseling which has a great impact on 
risk perception, albeit, counseling should be conducted on a wider variety of 
hereditary disorders. 








Chapter 2: Methods 
2.1 Purpose of the Study 
This study was designed to establish and/or confirm the pathogenesis of 
disease-causing mutations in genes underlying autosomal recessive disorders in UAE 
and to understand the mechanisms by which these mutations may cause the 
phenotypes. 
The approach in this dissertation is a mixture of experimental and qualitative 
approaches, planned to prove the main hypothesis which states that autosomal 
recessive single-gene disorders are most likely caused by biallelic loss-of-function 
mutations in the underlying genes within the genomes of the affected individuals. 
This is a phenomenological study focusing on ideographic cases to 
understand and explain the participants’ disease states. 
2.2 Research Design 
2.2.1 Settings and Participants 
 This study took place in Al Ain city within the emirate of Abu Dhabi, part of 
the UAE confederation. The participants were recruited from Tawam hospital (Al 
Ain) through Prof. Lihadh Al-Gazali. The affected individuals are from the pediatric 
category suffering from different autosomal recessive disorders.  
It is generally accepted that the number of samples is determined by the type 
of the study.  In rare diseases, the number of samples required is much smaller than 
other diseases. In our study, one of the diseases has a prevalence as low as <1 in 






prevalence. Although it is always favorable to have larger number of samples from 
unrelated families in the gene discovery for rare diseases, that is often not possible 
due to their rarity, and current technologies may allow gene discovery in one or two 
families, even in a single case in some situations. For example, in Kabuki syndrome 
only 10 patients were sequenced to identify 7 de novo variants in MLL2 gene 
(MacArthur et al., 2014). 
In summary, this investigation is open and flexible to more cases if available, 
thus, accumulating more cases suffering from the same genetic disorder will assist in 
a more comparative analysis and provide support to our findings, which is referred to 
as discriminate sampling.   
2.2.2 Sampling Techniques 
 Bio-samples collected for this study were mainly blood and fibroblast cells 
from affected and non-affected family members, when available. Whole blood 
samples were collected at Tawam Hospital in the city of Al-Ain in anti-coagulant 
treated tubes (ethylenediamine tetra acetic acid, EDTA) with lavender tops for DNA 
and RNA extractions. In some cases, fibroblast cells were collected by skin punch 
biopsy from patients’ skin and kept in 20% Dulbecco's Modified Eagle Medium 
(DMEM) and sent directly to our laboratory for processing and culturing. 
2.2.3 Permission and Consent Forms 
 Informed written consents were obtained from the parents of all the recruited 
affected minors. The risks to the participating families is minimal and blood samples 
often collected as part of their routine workup, and in any case the magnitude of 






psychologically. Written consents for publications, where required, were also 
obtained from the parents. 
2.2.4 Ethical Considerations 
 This study was approved by Al-Ain District Medical Human Research Ethics 
Committee (AAMD/HREC 10/09 and ERH-2015-3241 15-115). The study presented 
minimal risk to all participants and the procedures were fully explained to them. 
Information sheet about the study in both Arabic and English languages were 
provided to the families. Confidentiality was consigned from the initiation of the 
research work to the release of the results in the form of scientific publications. 
2.3 Details of Techniques and Methodologies Used 
2.3.1 DNA Extraction  
2.3.1.1 DNA Extraction from White Blood Cells 
 Genomic DNA was purified from peripheral blood leukocytes following the 
Flexigene DNA extraction kit protocols (Qiagen. Gmbh, Germany). The protocol 
starts by lysing cells with the provided lysis buffer (FG1), then centrifugation of the 
sample and discarding the supernatant, this could be repeated until major cell debris 
and some contaminants are washed away completely. A master mix of protease and 
lysis buffer 2 (FG2) was prepared and added then the mixture was incubated at 65 ºC 
for 5 minutes to digest the contaminating proteins. DNA was then precipitated by 
adding 100% iso-propanol, and the pellet washed further with 70% ethanol. To 
dissolve the DNA pellet, the provided buffer 3 (FG3) was added and incubated at 65 
ºC for 1 hour to dissolve the DNA into the aqueous solution. DNA concentration and 






Fisher Scientific, USA), the absorbance of DNA/protein (A260/280) with good DNA 
quality sample should be around 1.8 A260/280, and DNA to salts purity (A260/230) 
should be more than 2.5. 
2.3.1.2 DNA Extraction from Gel 
 The protocol used was the described and provided by the manufacturer for 
the MinElute Gel Extraction Kit (Qiagen. Gmbh, Germany), which aims to extract 
DNA fragments from gel by excising the fragment of interest under the UV light, 
using a sterile scalpel. After measuring the Eppendorf tube weight before and after 
the inclusion of the gel, 3 volumes of buffer QG were added to one volume of gel 
and incubated at 50 ºC for 10 minutes or until dissolved. Then one volume of iso-
propanol was added and mixed by inversion. The sample was then applied to 
MinElute column fixed on the vacuum manifold until all liquid had passed. 500 µl of 
buffer QG was added under vacuum, followed by 750 µl of PE buffer. The columns 
were placed in clean 1.5 ml microcentrifuge tubes and DNA was collected after 
adding 10 µl of EB buffer to the center of the membrane, let stand for 1 minute and 
DNA collected by centrifugation. 
2.3.2 RNA Extraction 
Total RNA was extracted from whole blood using SV Total RNA Isolation 
system (Promega, USA). This method provides a fast and simple way of isolating 
total RNA from blood and tissues. Briefly, blood collected in EDTA-treated tubes 
was lysed with buffer 1 (FG1) from the kit and the supernatant discarded in the same 
way mentioned earlier for DNA extraction. However, RNA lysis buffer was added 
here and incubated in ice for 15 minutes. Then RNA dilution buffer was then added 






95% ethanol added to precipitate the RNA, transferred to a column and washed with 
RNA wash buffer. To reduce genomic DNA contamination, DNAase I was added, 
followed by RNA washing then elution. For a good quality RNA, the 260/280 ratio 
should range between 1.8 and 2.2. In cases of extracting RNA from cultured cells, 
cells were detached, washed with 1x phosphate buffered saline (PBS), pelleted and 
RNA lysis buffer added and method performed as described above.  
2.3.3 Protein Extraction from Cultured Cells 
 Forty-eight hours post-transfection, either HEK293T or HeLa cells were 
scraped and washed twice with ice-cold PBS. To the cell pellets, 200 μl of ice-cold 
RIPA lysis and extraction buffer (Thermo Fisher Scientific, Waltham, MA) was 
added. In case of extracting nuclear proteins for co-immunoprecipitation studies 
(CO-IP), 1% in-house Triton X-100 was used with 10% of protease inhibitor cocktail 
(SigmaFAST Protease Inhibitor Cocktail Tablets, EDTA-Free; Sigma S8830) then 
incubated at 4 ºC on a rotator for 1 hr. For CO-IP, the lysate was sonicated at 20% 
power for 10 seconds in Sonic Ruptor homogenizer (www.Omni-inc.com), then the 
extracts were centrifuged at 4 °C on 14,000 x g for 20 minutes. Supernatants 
containing the extracted proteins were then transferred into fresh 0.5 ml tubes and 
kept at -80 ºC. 
2.3.4 Protein Concentration from Cultured Cells Media 
 Extracellular secreted proteins were collected and concentrated from the 
supernatants of cultured cells using Amicon Ultra-15 Centrifugal Filter Devices 
(Merck Millipore Ltd, Ireland). These devices have the capability of retaining and 
concentrating proteins according to their molecular weight. The tubes selected for 






kDa. Each tube can hold 15 ml of media collected from the cultured cells wells, spun 
at 4,000 x g for 20 minutes. Subsequently, the concentrated solute was recovered 
from the filter device using a pipette as instructed. 
2.3.5 Protein Concentration Determination 
 Total protein can be assayed colorimetrically using Pierce™ BCA Protein 
Assay Kit (Thermo Fisher Scientific, Waltham, MA) by chelating copper ions with 
protein in an alkaline solution forming a light blue complex, measured by 
spectrometer. The standard protocol described in the manufacturer’s instructions was 
strictly followed. Standard curves are drawn using absorbance values of standards of 
bovine serum albumin (BSA) to calculate protein concentration. 
2.3.6 Co-Immunoprecipitation of Proteins 
 Co-immunoprecipitation (CO-IP) is one of the widely used techniques to 
detect protein-protein interactions using specific antibodies to indirectly capture 
bound proteins (bait) with the directly bound ones (fish), forming immuncomplexes 
that are pulled down by the effect of the antibody attached beads. The non-attached 
proteins are washed away leaving the protein of interest in the tube for further 
analysis (Phizicky & Fields, 1995) 
In the current study Anti-c-Myc Agarose slurry (Thermo Scientific, USA) 
was used to pull down c-Myc tagged proteins from whole cell lysates (WCL), by 
adding 50 µl of slurry to 150 µl of WCL after washing the slurry with sufficient 
volumes of TBST/Halt Protease & Phosphatase Inhibitor Cocktail (100x) (Thermo 
Scientific, USA) 3 times, centrifuging at 3000 x g for 2-3 minutes and decanting. The 






immuncomplex was washed again with TBST/Protease Phosphatase Inhibitor 
Cocktail three times to remove unbound protein. There are different elusion 
protocols that can be followed to elute the proteins out of the beaded antibodies, the 
one used in this experiment was the chemical elusion using the non-reducing buffer 
(product # 1859594, Thermo Scientific, USA). 2X of the elusion buffer was added to 
the proteins, boiled at 98 ºC for 5 minutes, chilled, centrifuged at 3000 x g for 2-3 
minutes and supernatant containing the proteins, only, collected and loaded in the 
wells.  
2.3.7 Oligonucleotide Primer Design 
 DNA or complementary DNA (cDNA) primers were designed using Primer3 
software (www.primer3.ut.ee) (Untergasser et al., 2012) to amplify by PCR the 
genomic regions harboring the identified variants. The designed primers were 
ordered from Metabion Inc, Germany (http://www.metabion.com/). 
 On the other hand, site-directed mutagenesis (SDM) primers were designed 
using PrimerX (www.bioinformatics.org/primerx/) and the primers and probes used 
for the real time PCR experiments were ordered from TaqMan Real-Time PCR 
Assays (Thermo Fisher Scientific, Waltham, MA).  
2.3.8 General PCR Protocol 
 Upon receipt of primers, the desired DNA or cDNA fragments to be 
sequenced were amplified using Taqman polymerase kit (Qiagen. Gmbh, Germany). 
In general, 0.5 µl of DNA is added to 2 µl of 10x buffer and 4 µl of Q buffer/5% 
Dimethyl Sulfoxide (DMSO) (New England BioLabs, USA) or Betaine (Sigma, 






0.1 µl of Taq polymerase, and 0.6 µl of each of forward and reverse primers were 
added and the reaction mixtures topped to 20 µl total volume by nuclease free water. 
In the case of cDNA amplification, the template was added to 5x GoTaq® Flexi 
buffer (Promega, USA) to 25 µM MgCl2, 0.25 µl GoTaq® Flexi DNA polymerase 
(Promega, USA), dNTPs and primers to a total volume of 25 µl. 
The reaction tubes were transferred to the Veriti thermal cycler (Applied 
Biosystems, USA) and 35 amplification cycles were run as follows; an initial 
denaturation at 95 ºC for 5 minutes, followed by 94 ºC for 30 seconds and annealing 
for 30 to 45 seconds at variable temperatures depending on the melting temperatures 
of the PCR primers, then the elongation step at 72 ºC for 45 seconds followed by 
final extension at 72 ºC for 7 minutes, finally, tubes were kept at 4 ºC until analysis 
or appropriate storage. 
2.3.9 PCR Products Purification 
 This protocol was performed to purify double-stranded DNA fragments from 
PCR reactions when required. PCR DNAs are purified from unused primers, 
nucleotides, polymerases and salts. The procedure in this study was strictly followed 
according to the manufacturers of the MinElute PCR Purification Kit (Qiagen, USA). 
To each volume of PCR, 5 volumes of buffer PB were added and the mixture 
assembled on the vacuum manifold and vacuum applied. The membranes were then 
washed by adding 750 µl of buffer PE. To remove the residual ethanol from PE 
buffer, the columns were transferred into 1.5 ml microcentrifuge tubes and spun at 
10,000 x g for 1 minute. The last step was eluting DNA by adding 10 µl of buffer EB 







2.3.10 Reverse Transcription of mRNAs 
Reverse transcription refers to the conversion of mRNA into cDNA using 
reverse transcriptase (RT) enzymes, which were initially discovered in retroviruses 
owing the capability of reverting their RNAs back into DNA to integrate into the 
host’s genomic DNA. 
Random primers were added to previously normalized RNA samples and the 
mixtures were heated at 70 ºC for 4 minutes to denature the RNA secondary 
structures, then chilled on ice for 5 minutes. Next, a master mix of 0.5 µl GoScript 
reverse transcriptase enzyme 1 µl RNasin Ribonuclease Inhibitor, 4 µl GoScript 
buffer and 4 µl MgCl2 (Promega, USA), were added to the previous mixture and run 
in the PCR machine. The reaction starts at 25 ºC to anneal the primers to the RNA 
for 5 minutes, heated up at 42 ºC for 60 minutes to synthesize the new strands. The 
reaction is terminated by increasing the temperature to 70 ºC for 15 minutes to 
inactivate RT enzyme.  
2.3.11 Real-Time Quantitative PCR  
 In this study, comparative quantitation of mRNAs after conversion to cDNAs 
was performed in some cases to study the gene expression of the target genes. Data 
was generated as fold change among the patient and the normal control using 
hypoxanthine phosphoribosyltransferase gene (HPRT) or Glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) as endogenous controls since they are both 
house-keeping genes that are constantly expressed in cells. 
TaqMan PCR universal buffer (Applied Biosystems, Carlsbad, CA) contains 






exact components and their concentrations can be found in the TaqMan assay 
brochure. 
TaqMan probe is an oligonucleotide that contains a reporter dye at the 5’ end 
and a florescent quencher at the 3’ end. Once the primer binds to the template and the 
strand synthesis begins, the nuclease activity of the Taq polymerase will cleave the 
probe releasing the quencher dye from the reporter dye, hence, giving a signal of 
amplification. This reaction is repeated in 40 cycles, and if a signal exceeded the 
threshold it will then be considered as a real signal, referred to as threshold cycle 
(Ct), this occurs in the exponential phase until no more cDNA is amplified (plateau 
phase).  
In Real-Time PCR, the patient’s RNA as well as the control should be 
normalized prior to starting the RT-PCR reactions. Normalization is performed first 
by measuring its amount using nanodrop spectrometer, and by pipetting equal 
concentrations of all RNA samples, then performing reverse transcriptase explained 
in section (2.3.10). Then 2µl of cDNA were added to 10 µl of TaqMan universal 
master mix and 1 µl of TaqMan assay and topped up to 20 µl with nuclease-free 
water. At least, a triplicate of each sample should be used to calculate the mean Ct 
values as well as the standard deviation to measure the ∆∆ Ct values. The plate is 
then transferred to QuantStudioTM Real-Time PCR machine (Applied Biosystems, 
Carlsbad, CA), and the software did the data analysis and measurements including 
quality control (QC) analysis. 
2.3.12 Agarose Gel Electrophoresis 
 Once the targeted regions of the genome have been amplified by PCR, they 






molecular sizes. This method involves running a current through a prepared agarose 
gel using an electrophoresis device. The agarose gel itself is prepared by mixing the 
required agarose powder with water and ethidium bromide (EtBr) to reach a final 
concentration of 0.5 µg/ml. To estimate the size of the PCR product, the separated 
bands are compared to a standard ladder of DNA fragments of variable sizes, and 
viewed in Bio-Rad gel imaging system (Bio-Rad, USA). 
2.3.13 Sodium Dodecyl Sulfate Poly Acrylamide Gel Electrophoresis (SDS-
PAGE) and Western Blotting (WB) 
 SDS-PAGE is the most commonly used method to separate and analyze 
proteins (Saraswathy & Ramalingam, 2011). After proteins were extracted and their 
concentrations determined, an aliquot was added to Laemmli buffer containing 1.8 µl 
β-mercaptoethanol as a reducing agent, 2 ml glycerol, 0.5 M Tris-HCL, pH 6.8 and 6 
ml 20% SDS, the mixture was boiled at 98 ºC for 5 minutes to destroy the secondary 
and tertiary structures of the protein and give a uniformly negative charge. The name 
of the technique comes from the constituents of the gel, having 40% acrylamide/bis 
solution (Bio-Rad, USA), 1.5/0.5 M Tris-HCL, 10% SDS, 10% ammonium 
persulfate (APS), and ultra-pure N,N,N′,N′-Tetramethylethylenediamine (TEMED) 
(Invitrogen- Thermo Fisher Scientific, USA). 
Equal amounts of proteins were loaded into the wells of the SDS-PAGE gels 
along with the Biorad Precision Plus Protein Dual Xtra Standard (Bio-Rad, USA) 
and run in the in-house prepared 1x running buffer. To carry out Western blotting 
analysis, gels were then transferred onto a nitrocellulose membrane (GEHealth Life 






blotter. Later, membranes were washed and blocked in either 3% BSA (Sigma, USA) 
or 5% non-fat milk, depending on the type of antibody used. 
After blocking, the blots were incubated with primary antibodies over night at 
4 ºC, followed by washing steps with 1x Tris-buffered saline, 0.1% Tween 20 
(TBST) for 3 times then probed with the secondary antibodies for 1 hour at room 
temperature. Finally, the blot was developed using Pierce ECL western blot substrate 
(Thermo Fisher Scientific, Waltham, MA). Images were captured by Typhoon 
FLA9500Imager (GEHealthcare Life Sciences, Logan, UT). 
The loading controls used in all experiments were monoclonal mouse anti-
tubulin antibodies (dilution: 1:15,000; Santa Cruz Biotechnology Inc., USA), and 
polyclonal rabbit anti-GAPDH antibody (dilution: 1:2500: Abcam, UK). 
In order to investigate more than one protein on the same membrane and use 
different primary and secondary antibodies, one can strip the membranes using either 
gentle or harsh stripping protocols. In this study the harsh stripping protocol was 
performed on blots by incubating the membranes in a 55 ºC water bath after adding 
the following in-house reagents; 20 ml of 10% SDS, 6.5 ml Tris-HCL pH (6.8), 0.7 
ml β-mercaptoethanol (Sigma, USA), and topped up to 100 ml with water. The 
mixture was incubated with the membrane for 15 minutes, discarded and re-topped 
with fresh mixture again. Later, the membranes were washed with running tap water 
for 15 minutes, then with distilled water for 5 minutes, followed by three times wash 
with 1X PBS. To reprobe the membranes with other antibodies, they were first 






2.3.14 Direct Sanger Sequencing of PCR Products and cDNAs 
 Amplified DNA or cDNA fragments were sequenced with the relevant 
primers using the Sanger chain termination method on the 3130xl Genetic Analyzer 
(Applied Biosystems, USA). 
 The PCR products were cleaned up with Exonuclease 1/Shrimp Alkaline 
Phosphatase (Exo/SAP-IT) enzymes (Applied Biosystems, USA) to remove the 
unused oligos and dNTPs. This step was followed by the cycle-sequencing reaction 
where we added 1 µl of Big Dye Terminator to the mixture and kept on ice for 30 
minutes. Then 5x buffer, water and primers were added and run on the PCR machine. 
Afterwards, purification step was performed by adding 125 mM EDTA and 95% 
ethanol to precipitate the resulting DNA fragments. The reactions were then 
incubated at -20 ºC for 30 minutes, spun, decanted, and washed by 70% ethanol. 
Sanger sequencer sequences one strand, thus, to denature the other, 15 µl formamide 
was added and heated at 96 ºC. 
The results were generated as chromatograms and nucleotide sequence 
documents were further aligned and analyzed using BioEdit software and Clustal 
Omega algorithms (www.ebi.ac.uk/Tools/msa/clustalo/) (Sievers et al., 2011). 
2.3.15 Plasmid Sanger Direct Sequencing 
 The used human cDNA clones were purchased from Genecopoeia 
(GeneCopoeia, Rockville) (www.genecopoeia.com) and OriGene (OriGene, USA) 
(www.Origene.com). The plasmids were supplied lyophilized as well as their 






competent E. coli cells for amplification and then extracted with plasmid Miniprep 
kit (Qiagen, USA). 
Extracted plasmids were directly sequenced after cutting with the appropriate 
restriction enzyme, then 4 µl of the plasmid DNA was added to 2 µl of either 
primers, 2 µl of Big Dye Terminator and 5x buffer. The mixture was then run on the 
PCR machine at 90 ºC for 5 minutes as initial denaturation step, followed by 30 
seconds, then at 60 ºC for 4 minutes, the cycle is repeated 35 times. The final step 
before loading the sequencer should be the purification step as mentioned earlier.  
2.3.16 Whole Exome Sequencing 
 Whole Exome sequencing for families 3 and 4 was performed at Sengenics, 
Kuala Lumpur, Malaysia (www.sengenics.com) on the affected children of families 3 
and 4 using the Illumina HiSeq 2500 platform, sequencing the coding regions of the 
DNA (exons) which comprise 1-2% of the whole genome and which is expected to 
harbor more than 90% of the disease-causing mutations. 
With a powerful, high-throughput system, HiSeq 2500 can sequence 5-75 
exomes per run. Starting with library pooling and exome enrichment with 2.5 days 
turn-around time, followed by (sequencing by synthesis method) which lasts for 5 
days, and ultimately analyzing alignment, detecting structural aberrations  and 
CNVs, as well as variants annotation using software calculation systems which takes 
from 2-3 hours (www.illumina.com).  
10 µg of high quality total genomic DNA of each sample was submitted with 
a total concentration of 50-200 ng/µl. The quality of the submitted DNA samples was 






Whole Exome sequencing on families 1 and 2 was conducted as a service at 
Baylor College Genetics Laboratory (www.bcmgeneticlabs.org) on the affected 
children and the following quality control metrics of sequencing data were generally 
achieved: >70% of reads aligned to target, >95% target base covered at >20x, >85% 
target base covered at >40x, mean coverage of target bases >100x. As a quality 
control measure, the individual’s DNA was also analyzed by SNP-array, and 
compared with the WES data, SNP concordance to genotype array: >99%. The test 
might not provide detection of certain genes due to local sequence characteristics or 
presence of closely related pseudogenes. Gross deletions or duplications might have 
not been accurately identified by this methodology. 
2.3.17 Whole-Genome SNP Genotyping and Homozygosity Mapping 
 SNP genotyping was performed as a service by ATLAS Biolabs, GmbH , 
Germany (www.atlas-biolabs.com) using Genome Wide Affymetrix SNP 6.0 
genotyping assay, which  can detect around 900 K SNPs and 900 K CNV markers. 
 DNA samples of all available family members (affected and non-affected 
members) were submitted with high quality DNA, the data was generated as wild-
type SNP allele (A) and the alternative allele (B). Affymetrix 6.0 utilizes intensity 
QC metrics and signature SNP genotype calls to assure the quality control. The QC 
analysis provides an estimate of the overall quality for a sample based on the contrast 
QC algorithm as the primary method, in addition to the dynamic model algorithm. 
Contrast QC criteria have a Birdseed genotyping call rate of at least 97% and an 
accuracy of at least 99% (with average performance significantly higher) when 
analyzed with Genotyping Console at default settings. Contrast QC is the 






threshold is >=0.4 for each sample. Gender analysis was also performed during the 
QC step. It provides a gender call that will be used to select models for the X and Y 
chromosomes during genotyping. The Genome-Wide Human SNP Array 6.0 
contains SNPs and CN probe sets from two enzyme sets (Nsp and Sty). Some SNPs 
and CN probe sets are only present on fragments generated by one of the enzymes, 
while other SNPs and CN probe sets are present on fragments generated from both of 
the enzymes. There are situations where a sample may work properly with one 
enzyme set, but not with the other. Different processes are used for the gender call, 
depending upon the type of array being analyzed. Genotyping Console supports 
genotyping analysis for Birdseed v1 or Birdseed v2 algorithms.  
Subsequently, data was uploaded in the homozygosity mapper software 
(www.homozygositymapper.org). The Genome Wide SNP 6.0 chip was selected, and 
the analyzed patients’ IDs were checked as cases, while the healthy were checked as 
controls. Selecting the default settings was accurately sufficient to get the runs of 
homozygosities across the genomes, they included checking genetic homogeneity 
option to detect regions in which all the affected individuals were homozygous. 
Regions with the disease haplotype were excluded if they were longer than 4000. In 
order to count all the homozygous blocks, the lower limit of length was selected as 
zero. The resulting graphical interfaces were obtained from GeneDistiller where all 
candidate genes in long homozygous regions were queried. To emphasize interesting 
regions, scores higher than 80% of the maximum score were shown in red, whereas 
smaller decreases of the score within a homozygous region were neglected (black 
bars). GeneDistiller provided generous information on the proteins and their 







(Alkuraya, 2010).  
2.3.18 NGS Variants Filtration and Pathogenicity Prediction 
 The sequenced reads were aligned to human genome version 19 (hg19). 92% 
of the sequenced bases have a quality score more than 30 (Q30), Q score refers to the 
probability of a correct call, with greater sequencing depth. 
 After excluding CNVs and other structural variants by CGH array, runs of 
homozygosity (ROH) were applied on the WES data by detecting stretches of 
homozygous genotypes using DNA markers at consecutive positions spanning one 
marker every 3 kb or less. The graphical interface of the results presented by bar 
graphs could be zoomed to view the chromosomes harbored. Such that the red bars 
(exceeded the threshold) were included, whereas the black ones were not. 
Furthermore, segments of sizes more than 2 cM were included in the study (Woods 
et al., 2006). The downstream variants’ filtration and prioritization has been 
conducted by Al-Jezawi N. K, by establishing an integrated WES data filtering 
approach aiming first to extract essential variants calls such as missense, stop gained, 
frameshifts and splice-site variants, thus excluding deep intronic, synonymous, and 
variants located at the 3 prime UTRs, compared to the exome variant server 
(www.evs.gs.washington.edu), the 1000 Genome project 
(www.browser.1000genomes.org), GalaxC (www.galaxc.sengenics.com), ExAC 
database (www.exac.broadinstitute.org) and GME variome project 
(http://igm.ucsd.edu/gme/). Variants with minor allelic frequency (MAF) more than 






 The predicted effects of the identified variants on the protein function were 
identified using SFIT, PolyPhen, Provean, Mutation Taster and FATHMM. The non-
damaging, tolerated or benign variants were excluded. More Bioinformatics analyses 
were performed, and are demonstrated in later sections. 
 A very important criterion in filtering was to find out damaging variants, if 
any, that existed in a homozygous state of the candidate genes in normal individuals, 
inferring a dispensable role of the resulting protein. At a final stage, all the candidate 
genes were cross-matched in the affected siblings as well as performing segregation 
analyses by genotyping using Sanger sequencing on all the family members.  
2.3.19 Comparative Genomic Hybridization 
 CGH array was performed as a service at Sengenics (www.sengenics.com) on 
patients’ DNA samples using Chip microarray, using test and control genomes which 
were differently labelled and hybridized to a microarray chip. This florescent chip 
was later scanned and measured by a software. CGH is used to study CNVs and 
other structural aberrations in the human genome. 
2.3.20 Cell Culture and Transient Transfection 
 The primary cell lines used in this study were normal control or patients’ 
fibroblasts derived from skin biopsies. Commonly available cell lines were also used 
for some experiments including HEK293T, HeLa and SH-SY5Y cells. Cells were 
maintained in DMEM supplemented with 10% fetal bovine serum, 4mM L-
Glutamine, 4,500 mg/L Glucose, Sodium Pyruvate, and 100 U/ml 
Penicillin/Streptomycin. For SH-SY5Y cells, they were maintained in DMEM/F12 






were passaged every 3 days upon reaching 70-80% confluency. HeLa and SH-SY5Y 
cells used for immunofluorescence assay were seeded on 24-well plate sterilized 
coverslips, incubated for 24 hours, followed by transfection with the wild and the 
generated mutants. On the other hand, HEK293T and fibroblast cells which were 
used for protein extraction and western blot analysis, were seeded with a density of 
2.5 × 105 cells/well in 6-well plates for 48 hours. HEK293T cells were transfected 
with the needed plasmid using the Promega, Madison, WI, FuGENE HD transfection 
kit (Promega, USA), with a DNA/FuGENE ratio of 1:3, respectively. 
2.3.21 Site Directed Mutagenesis 
 Mutations generated in the cDNA plasmid constructs were performed with 
Pfu Ultra High-Fidelity DNA polymerase (Stratagene, USA). 20 ng of the template 
plasmid was added to 0.5 µl of each of the designed primers, 0.5 of the dNTPs 
mixture, 2.5 µl of the 10x Pfu Ultra Buffer, 5 µl Q-solution and 0.5 µl of the Pfu 
enzyme. The reaction was later run on the PCR thermocycler on the following 
program; initial denaturation at 95 ºC  for 5 minutes, denaturation at 94 ºC  for 30 
seconds, followed by annealing for 1:30 minutes, and ending with the elongation step 
at 70 ºC  for 18 minutes and post-elongation at 72 ºC  for 20 minutes, repeating them 
20 times. 
 Subsequently, mutagenesis PCR products are cleaned up from the remaining 
templates using DpnI enzyme (0.3) µl with the PCR product (10 µl) for 3-4 hours. 
These products were used to transform E. coli ultra-competent cells and colonies 
were picked and their plasmids were tested, by direct DNA sequencing, for the 






2.3.22 Plasmid Transformation and Purification 
 Plasmids, either wild types or mutants were transformed into E. coli 
competent cells on ice during log phase for 30 minutes, then heat shocked at 42 ºC 
for 45 seconds. After the cells were chilled again, 500 µl of Laurel broth (LB) was 
added with 2 µl of 1 M glucose (Sigma, USA) per ml and incubated shaking at 37 ºC 
for 30-45 minutes. Afterwards, tubes were centrifuged at 4000 RPM for 5 minutes to 
collect the sediment then they were streaked onto LB-agar plates for no longer than 
16 hours. 
On the next day, single colonies were inoculated in LB broth supplemented 
with 1 µl of the relevant antibiotic per 1 ml of the broth, and kept shaking at 37 ºC 
for 16 hours. 
On the following day, plasmid extraction was performed following the 
manufacturer’s instructions for Miniprep kit (Qiagen, USA). The bacterial cells were 
collected after centrifuging the tubes at 4000 RPM, 4 ºC  for 6 minutes. Supernatants 
were discarded and 250 µl of P1 buffer was added to each tube to lyse the bacterial 
cells, mixed and transferred into a 1.5 µl centrifuge tube. Then 250 µl of P2 buffer 
was added, followed by 350 µl of N3 buffer to neutralize the lysate, clumps were 
formed, then the lysate was separated by centrifugation at 12,000 RPM for 10 
minutes. To remove the endonucleases, 0.5 ml PB buffer was added while the tubes 
were assembled in the column tube supported on a vacuum pump. Subsequently, 
salts were removed efficiently by adding 0.75 ml of PE buffer. Finally, plasmids 






2.3.23 Confocal Microscopy 
 Transfected HeLa or SH-SY5Y cells grown on coverslips were washed three 
times with PBS, fixed with methanol for 5 min at −20 °C, and blocked by 2% BSA 
for 1 hour. Specific primary antibody dilutions were added to the cover slips as the 
primary antibody, part of them were incubated with ER marker anti- calnexin goat 
(C20) polyclonal antibody (dilution: 1:50; Santa Cruz Biotechnology Inc., Dallas, 
Texas) whereas, the rest were incubated with the Golgi marker anti- Golgin-97 
mouse monoclonal antibody (dilution: 1:100; Cell Signaling Technology,Danvers, 
MA). For Myc-tagged proteins, mouse-anti-Myc-tag monoclonal antibody (dilution: 
1:200; Cell Signaling Technology) were added. Whereas in case of using antibodies 
against the XYLT1 protein, Polyclonal rabbit anti-XYLT1 antibodies were used 
(dilution: 1:50; Sigma, USA), all were incubated for 1 hour at room temperature in 
dark. In other experiments where plasma membrane localization was studied, GFP-
H-Ras plasmids were used by mixing 0.3 µg of plasmids with Gibco™ Opti-MEM™ 
I Reduced Serum Media (Opti-MEM) followed by 3:1 ratio of FuGENE:DNA, 
respectively. Moreover, another plasmsa membrane marker was used that is 
ubiquitously expressed in cells, that was rabbit polyclonal sodium/potassium-ATPase 
(Na+/K+-ATPaseα (H-300): sc-28800) (Santa Cruz Biotechnology Inc, USA). Cells 
were then washed three times with PBS and incubated with the following respective 
secondary antibodies for 45 minutes at room temperature in dark: Anti-rabbit IgG 
(H+ L) F(ab)2 Fragment (Alexa Flour 488 conjugate) (dilution: 1:1000; Cell 
Signaling Technology, Danvers, MA) to respective wells, anti-mouse IgG (H + L) 
F(ab)2 Fragment (Alexa Flour 555 conjugate) (dilution: 1:1000; Cell Signaling 
Technology) to respective wells, and anti-goat IgG (Alexa Flour 555 conjugate) 






Subsequently, cells were washed and mounted with immunofluor medium (ICN 
Biomedicals). Between 100 and 200 transfected cells for each construct were 
inspected and at least images of 10 cells were acquired using Nikon confocal Eclipse 
80I microscope (Japan). Some experiments were performed in duplicates, others in 
triplicates and in some cases even more. 
2.3.24 Cloning and Construction of the Mini-Gene Vector 
 To assess splice-site variants when patients’ cells were not available or 
inaccessible, hybrid mini-genes have been developed to determine the impairment of 
suspected variants on the splicing machinery (Deguillien et al., 2001).  
 In the current study, the splicing cassette (p(13,17)/CMV) was designed by 
Deguillies and colleagues using pRc/CMV, 5.5 kb plasmid, where exons 13 and 17 
with their downstream and upstream flanking intron of the erythrocyte membrane 
protein band 4.1 gene (4.1R/EPB41) were cloned (Deguillien et al., 2001). One of 
our variants (c.394G>A) of Multiple PDZ domain gene (MPDZ), was located on the 
first nucleotide of exon 5, and this variant was a component of a compound 
heterozygous mutations leading to a hydrocephalus case of one patient. One possible 
implication of this variant was to cause a splice-site effect on the mRNA level, and 
therefore to examine that, exon 5 and parts of its flanking introns were sub-cloned 
into the mini-cassette vector which harbors exons 13 and 17 and their flanking 
introns of  (EPB41).  The intron between exons 13 and 17 has multiple cloning sites 
including restriction sites for BSTEII (GGTCACC) and NheI (GCTAGC) enzymes 
(New England Biolabs, USA). Thus, cloning primers were designed containing those 
REs. Forward primer: 5’-ATGTGGGTCACCACACTTACTAAG-3’, Reverse 






were not within the desired fragment, after amplifying the genomic fragment of 
MPDZ gene from a normal control genome which was around 647 bps, and which 
was performed by adding 1 µl of Pfu Ultra High-Fidelity DNA polymerase 
(Stratagene, USA), to 1 µl of dNTPs, 1.6 µl of each of the forward and reverse 
primers, 5 µl of 10x Pfu Ultra Buffer, and 1 µl of DNA, then topped with water to a 
total volume of 50 µl, the reaction was run on the thermo-cycler using the following 
PCR program; initial denaturation at 95 ºC for 5 minutes, followed by denaturation at 
94 ºC for 30 seconds, then the annealing step was adjusted according to the Tm of 
the primers for 1:30 minutes, further step was the elongation at 72 ºC for 1:30 
minutes (2 min/Kb), and a final elongation for 7 minutes. The product was further 
purified using MinElute PCR Purification Kit (Qiagen. Gmbh, Germany). 
Meanwhile, the respective enzymes were checked from Double Digest Finder 
(www.neb.com) and found to be non-compatible, so a sequential digestion was 
required, starting with the enzyme of lower temperature (NheI) with an optimal 
temperature of 37 ºC. Separate reactions were attempted for the vectors and the 
insert, such that 1 µg of the vector and separately, all the amount of the insert were 
added to 1 µl of NheI with 5 µl of BSA and 5 µl of 2.1 buffer (New England Biolabs, 
USA), then topped up with water to 50 µl reaction and incubated at 37 ºC for 2 
hours. The enzymatic reaction was stopped by deactivating the reactions at 65 ºC for 
15 minutes. Directly after, the digested vector was checked on gel electrophoresis to 
view the linearized cut vector appearing ‘heavier’ compared to the non-digested. The 
next step was applying the second enzyme (BSTEII) by adding 1 µl of the enzyme 
and 5 µl of 3.1 buffer to the previous reaction and incubated for 2 hours at 60 ºC, 
then deactivated similarly. To detect that the vector was cut, it was run on gel along 






molecular weight. Subsequently, gel purified using MinElute Gel Extraction Kit 
(Qiagen. Gmbh, Germany). 
The PCR product of MPDZ gene was then ligated to the vector using 1 µl of 
T4 DNA ligase, and a molar ratio of vector/insert ranging from 1:3-1:15, calculated 
using in silico ligation calculator (www.insilico.uni-duesseldorf.de). To the previous 
mixture, 2 µl of T4 DNA ligase buffer was added and topped with water to 20 µl. 
The reaction was optimized at two different conditions; at RT for 30 minutes or at 
16 ºC overnight. Eventually, all the attempted plasmid clones were transformed, 









Figure 8: An illustration for the preparation of the recombinant plasmid for mini-
gene construct. A) A schematic model of the mini-cassette plasmid with the cloned 
13 & 17 exons of EPB41 gene. B) The digestion steps using NheI then BSTEII on 
the vector, a linearized plasmid observed after the nicking appearing at a higher 
molecular weight. C) The ligation of the vector with exon 5 and its flanking introns 
of MPDZ gene showing higher molecular weight (6.6 kb) owing to the insertion of 
647 bp. 
To generate the mutant construct, site-directed mutagenesis (SDM) was 
performed on the vector harboring the wild-type MPDZ using the following primers: 
Forward primer: 5’-TCCTAAACAGAGTCGCCATG- 3’, Reverse primer:  5’-
CATGGCGACTCTGTTTAGGA-3’, the mutant vector was as well sequenced to 
confirm mutagenesis.  
HEK 293T cells were maintained in DMEM, supplemented with 10% fetal 






U/ml Penicillin/Streptomycin. Then they were seeded in 6-well plate. On the 
following day, wells were transfected with the wild-type minigene construct, while 
the others were transfected with the mutant and cultured for 24 hours at 37 °C, 5% 
CO2. The following day, cells were scraped and washed with PBS and RNA was 
extracted using SV Total RNA Isolation system (Promega, USA), then reverse 
transcribed with random primers and GoScript reverse transcriptase enzyme 
according to the manufacturer’s instructions (Promega, USA). Subsequently, the 
resulting cDNA was analyzed on agarose gel electrophoresis and sequenced with the 
following primers; F: 5’ GTGGTCCCTAAGGCACAGAA 3’ and R: 5’ 
CCGTGGTTCGGGTACCG 3’ to assess RNA splicing. 
2.3.25 Glycosidases Sensitivity and Resistance Assays 
There are many enzymes that are used to study the structure and function of 
glycoproteins, among which are the endoglycosidase H (Endo H), Endo D, Endo F2, 
Peptide N-glycosidase F (PNGase F), etc. Each of them cleaves at specific site of the 
glycans. For example, Endo H cleaves between two N-Acetylglucosamines 
(GlcNAc) leaving one residue attached to the asparagine (Asn) residue of the protein. 
This assay is used experimentally to determine if glycoproteins contain high-
mannose or hybrid oligosaccharides to distinguish ER and post-ER passage. So any 
glycoproteins that progress to later Golgi (medial and trans-Golgi apparatus) stages 
become more resistant and therefore the glycan moiety becomes resistant to cleavage 
by Endo H. Whereas PNGase F enzyme can cleave all the carbohydrate chains 
leaving only asparagine converted to aspartate, thus, even complex glycans are 
sensitive to it. The cleavage sites of the various glycosidases are illustrated in 







Figure 9: Illustration of the glycosidase enzymes. A) Endo H cleaves between two 
GlcNAcs leaving one attached to the asparagine. Whereas, PNGase F cleaves 
between the GlcNAc and asparagine releasing all the glycan chain from the core 
protein (www.sigmaldrich.com). B) A comparison between the different glycosidase 
enzymes on the high mannose versus complex and hybrid forms of glycoproteins 
(Freeze & Kranz, 2010). 
Endo H assay (Product Number A0810Sigma, USA) can be performed either 
on whole cell lysates or immunoprecipitates, in which case about 20 µg of protein 
was added to 2µl of denaturation buffer and were incubated at 98 ºC for 5 minutes to 
destroy the secondary and tertiary structures of the proteins. After chilling on ice, 8 
µl of sodium phosphate buffer was added to reach an optimum pH of 5.0-6.0. The 
sample was then divided into two tubes; one was left undigested, whereas 2 µl of 
Endo H enzyme were added to the other, both reactions were incubated at 37 ºC for 4 
hours. This assay is used to distinguish pre-Golgi forms (sensitive) from the post-






On the other hand, the most universal amidase is PNGase F, cleaving most 
complex structures except for α 1,3 fucose and the presence of one GlcNAc attached 
to asparagine. However, in some cases, the high molecular weight of this enzyme (37 
kDa) could limit its accessibility to the protein cleavage site (Thobhani, Yuen, 
Bailey, & Jones, 2009). 
To 1-20 µg of proteins, 1 µl of denaturing buffer (10x) was added and topped 
up to 10 µl with water and denatured at 100 ºC for 10 minutes. After chilling, 2 µl of 
GlycoBuffer 2 (10x), 2 µl 10% NP-40 and 6 µl of water were added. NP-40 was used 
to protect the enzymatic activity from the denaturation step. Next, 1 µl of PNGase F 
was added to the previous mixture and incubated at 37 ºC for 24 hours (New England 
Biolabs, USA). Digested proteins were subsequently checked by western blotting. 
2.3.26 Protein Structural Modeling 
 One of the approaches to add more evidence to the pathogenesis of variants in 
genetic diseases is protein structural modeling.  Protein modeling may allow the 
detection of both structural and functional changes of the protein of interest with 
genetic variation. This type of investigation was used as a class of evidence 
explaining the implication of variants in genetic diseases. 
 In this study, protein models were conducted by Dr. Ranjit Vijayan from the 
Department of Biology, College of Science, United Arab Emirates University using 
PyMOL (www.pymol.org) and Schrodinger Prime (www.schrodinger.com).   
 The protein structure of one of the affected domains in MPDZ protein was 






modeling), due to the unavailability of a human structure. In our case it was the rat 
PDZ4 structure (PDB ID: 4XH7). 
2.3.27 Bioinformatics and Computational Analysis 
Bioinformatics is a science of employing the power of computing to analyze 
biological data. Numerous bioinformatics softwares and programs have been 
developed over years to help with biodata analysis. Table 1 summarizes some of the 






Table 1: Classes of the main bioinformatics tools and databases used in this study 
Bioinformatics 
Tool/Resource 
Analysis Description Website 
Ensembl Genome 
Browser 
Genes annotations, alignments, predictions, disease data, 
sequence variations 
www.ensembl.org 
OMIM Human genes and genetic phenotypes, information about 
Mendelian disorders 
www.omim.org 
NCBI Gene organization, sequence analysis, structure prediction, 
mathematical modeling, sequence alignment, gene expression 
www.ncbi.nlm.nih.gov 
University of 
California Santa Cruz 
(UCSC) Genome 
Browser 
Visualizing genomic data, blast analysis, variant annotations, In 
silico PCR and more 
www.genome.ucsc.edu 
Uniprot Peptide search, blast, Alignment, protein sequence and 
functional information 
www.uniprot.org 
STRING Information on known and predicted protein-protein 
interactions 
www.string-db.org 







Table 1: Classes of the main bioinformatics tools and databases used in this study (Continued) 
Bioinformatics 
Tool/Resource 
Analysis Description Website 
ExAC Browser WES data of individuals excluding severe pediatric cases, 
useful reference for allelic frequencies 
www.exac.broadinstitute.org 
Exome Variant Server WES data and SNPs, variants information summarized 
according to different population, protein prediction 
www.evs.gs.washington.edu 
1000 Genome Browser A source of human genetic variation with frequencies more 
than 1% 
www.browser.1000genomes.org 
GalaxC Allele frequency database of Arab disease mutations www.galaxc.sengenics.com 
Clustal Omega Pairwise and multiple sequence alignment with either DNA or 
protein entry format 
www.ebi.ac.uk/Tools/msa/clustalo/ 
BLAST Compares nucleotide or protein sequences to databases and 
measuring the statistical significance 
www.blast.ncbi.nlm.nih.gov/Blast.c
gi 
Protein Atlas Demonstrates gene expression of transcriptomes and proteomes 








Table 1: Classes of the main bioinformatics tools and databases used in this study (Continued) 
Bioinformatics 
Tool/Resource 
Analysis Description Website 
Gene Cards Searchable database for all annotated human genes providing 
information on genes, transcriptomes, proteins and clinical 
information 
www.genecards.org 
SIFT and Provean Predict the effect of amino acid substitution by entering the 
chromosome number, genomic location and the nucleotide 
susbstitution 
www.provean.jcvi.org 
PolyPhen v2 Predicts possible impact of an amino acid substitution on the 
structure and function of a human protein by entering the 
protein identifier and the amino acid substitution 
www.genetics.bwh.harvard.edu/pph
2/ 
Mutation Taster Predicts the effect of substitutions, deletions or insertions, 
summarizes the allelic frequencies from different databases, 
scores the conservation among multiple species 
www.mutationtaster.org 
FATHMM Predicts the functional effects of missense variants on proteins www.omictools.com/fathmm-mkl-
tool 
Automated Splice Site 
and Exon Definition 
Analyses (ASSEDA) 





Table 1: Classes of the main bioinformatics tools and databases used in this study (Continued) 
Bioinformatics 
Tool/Resource 
Analysis Description Website 
Human Splice-Site 
Finder v2.4.1 
Predicts the effect of splice-site variants on mRNA and 
calculating the consensus values of potential splice-sites 
www.umd.be/HSF 
Neural Network Predicts the effect of splice-site variants on mRNA and giving 
scores of the cryptic splice-sites. 
www.fruitfly.org/seq_tools/splice.ht
ml 
Primer3 v 0.4.0 To design PCR primers www.primer3.ut.ee 
PrimerX To design mutagenic PCR primers www.bioinformatics.org/primerx/ 
Homozygosity Mapper Generating a report and a graph for the homozygous regions of 




Provides information about animal models with regard to 
mutations and many other useful applications 
https://www.jax.org 
cNLS Mapper Prediction of importin α-dependent nuclear localization signals http://nls-mapper.iab.keio.ac.jp/cgi-
bin/NLS_Mapper_form.cgi 
Gene Matcher Enables connections between clinicians and researchers around 








Chapter 3: Results 
 
3.1 Compound Heterozygous Variants in the Multiple PDZ Domain Protein 
(MPDZ) Cause a Case of Mild Non-Progressive Communicating 
Hydrocephalus 
3.1.1 Clinical Representation of the Studied Patient in Family 1 
The affected child was the first born to a non-consanguineous couple from 
the UAE (Figure 10A). The pregnancy was uncomplicated, but ultrasound at 20 
weeks of gestation revealed large head with dilated ventricles. Delivery was normal 
at term with a birth weight of 3400 gm, length of 56 cm, and head circumference of 
39 cm (>97th centile). There were no other reported neonatal problems. However, 
family history revealed that the brother of the mother has a daughter with 
hydrocephalus and ventriculoperitoneal (VP) shunt. Unfortunately, no further clinical 
or radiological information were available for this child because the family refused to 
participate in the research, and hence, no clinical or molecular studies were 
performed on this branch of the family.  
MRI brain at three months revealed widened cerebrospinal fluid (CSF) spaces 
in the frontoparietal region bilaterally, as well as mild dilatation of lateral and third 
ventricles (Figure 10B). The cerebral volume was preserved and the white matter 
appeared normal. These findings are believed to be consistent with external 
hydrocephalus. 
The patient was evaluated at Tawam Hospital Genetics Clinic at the age of 
nine months. His weight at the time was 10 kg (75th centile), length 77 cm (90th-






large head with frontal bossing and high arched palate, but no other dysmorphic 
features. He had normal developmental milestones and at the age of 14 months he 
was walking and saying a few words, but continued to have a large head. At 15 
months his weight was 11.5 kg (>50th centile), height 84 cm (>90th centile) and 
head circumference 51 cm (>97th centile). Detailed ophthalmological examination 
was normal. Progress brain MRI at age 17 months showed less dilatation of 
ventricles and less widening of CSF spaces, in line with the natural progress of 
external hydrocephalus. Several clinical investigations were found to be negative, 
including microarray for CNVs and Indels, urine organic acid, urine 
mucopolysaccharides (MPS), creatine phosphokinase (CPK) and skeletal survey that 













Figure 10: Clinical and molecular analysis of Family 1 with CH. A) Pedigree 
showing the affected child with hydrocephalus for a non-consanguineous Emirati 
family. B) MRI (T1 weighted images), upper panels at age 3 months showing 
widened CSF spaces in the frontoparietal regions (white arrows), widened 
interhemispheric fissure (green arrow) and mild dilatation of ventricles (red arrow). 









3.1.2 Whole Exome Sequencing in the Affected Child Revealed Two Compound 
Heterozygous Mutations in the MPZD Gene 
Clinical whole-exome sequencing analysis was conducted at Baylor College 
Genetics Laboratory on the affected child, it revealed two compound heterozygous 
variants (c.394G>A and c.1744C>G) in the MPDZ gene. The output data from 
Illumina HiSeq were converted to FastQ files by CASAVA 1.8 software, and 
mapped by BWA program, the variant calls were performed using Atlas-SNP and 
Atlas-indel developed in –house by BCM HGSC. The variants were interpreted 
according to ACMG  guidelines (C. S. Richards et al., 2008) and patient phenotypes. 
For both identified variants, the minor alleles were not reported; neither in 3738 
African American (AA) nor in 7017 Europeans (EA). The report included minor 
allele frequency (MAF) data for variants reported in the NHLBI GO Exome 
Sequencing Project (ESP) ESP5400 database to be “1/3738 1/7017” in AA/EA, 
respectively. Both variants were absent in GalaxC database. Next, Sanger sequencing 
was performed on the whole family to confirm the segregation of these compound 
heterozygous variants with the child being compound heterozygous for both variants 
(Figure 11A). The mother was heterozygous for the c.394G>A variant (Figure 11B, 
left panels), while the father was heterozygous for the c.1744C>G variant (Figure 
11B, right panels). The first variant (c.394G>A) has been reported as a SNP 
(rs201101621) that was presumed to lead to the substitution of glycine at 132 with 
serine (p.Gly132Ser). However, this SNP has a minor allele frequency of T=0.0004 
based on 1000 genome, and no homozygotes were reported for this variation. In 
addition, computational analysis predicted that this variant is disease 
causing/damaging using Mutation Taster and SIFT/Provean software. More 






Neural Network software (www.fruitfly.org/seq_tools/splice). It predicted a score of 
0.78 for the acceptor splice-site present at c.394-1G, which is one nucleotide 
upstream to the variant. Furthermore, the software predicted that the variant might 
lead to the use of the cryptic acceptor-splice sites within intron 5-6 with a score of 
0.74, leading to skipping of exon 5 and the generation of a stop codon. We therefore 
aimed to discriminate between the two possibilities as the underlying molecular 
cause as illustrated in the following sections (3.1.3 and 3.1.4). 
The second variant (c.1744C>G) was predicted to cause a missense mutation 
at amino acid position leucine 582 to valine (p.Leu582Val).  At the same locus, a 
different SNP (rs201275925) has been reported with G/A alleles. This SNP has a 
minor allele frequency of A=0.0002. However, the change was synonymous. In silico 
analysis using Mutation Taster predicted that the p.Leu582Val variant was disease 
causing. However, SIFT/Provean predicted that the change is tolerable/neutral. The 
two identified variants (c.394G>A and c.1744C>G) were absent in Exome Variant 
Server for all the tested population.  Furthermore, there were no clearly damaging 
variants in MPDZ gene in a homozygous state in normal individuals in this database, 
suggesting the importance of this gene for human health. Likewise, there were no 
reports of any homozygous damaging variations at the same locus in MPDZ gene in 
NCBI. Additionally, analysis of the child’s WES data identified two variants in 
heterozygous states in genes known to be implicated in hydrocephalus. One of which 
was in CCDC88C gene (c.4327G>A) on chromosome 14, a previously reported 
reference SNP (rs189215037). This variant leads to an amino acid substitution 
(p.Ala1443Thr) which was predicted to be tolerated/benign by SIFT/PolyPhen-2 
tools with ESP5400 AA/EA frequency of 0/3086 16/6636. The other variant was 






tolerable amino acid substitution (p.Arg926Gln), but its frequency was not reported 
in ESP5400 AA/EA. In addition, the variants in these two genes were heterozygous 
and were not predicted to be disease-causing and therefore were excluded as relevant 
to the phenotype in the child. 
We wanted to further confirm the pathogenicity of the identified variants as 
well as elucidate their possible underlying molecular/cellular mechanisms.  
 
Figure 11: The chromatograms and illustration of the compound heterozygous 
variants in family 1 A) Illustration of the nature of the identified variants located at 
two different chromosomes (trans-configuration). B) A compound heterozygous 
mutation in the child c.394G>A (left panels), inherited from his mother and a second 
c.1744C>G mutation (right panels) inherited from his father. Parents are both carriers 
for each mutation (Red arrows indicate the positions of the variants). 
3.1.3 cDNA Sequencing Revealed a Likely Unstable Copy of the c.394G>A 
Mutant mRNA 
          We wanted to test the predicted effect of the c.394G>A variant on mRNA 
splice site; we therefore prepared and sequenced the MPDZ cDNA from the mother, 






was observed (Figure 12A). In addition, Sanger sequencing revealed a single 
sequencing peak (G) at position c.394 in all three cases (Figure 12B). This evidently 
was different to what we observed from the genomic DNA sequencing where the 
affected child and the mother were heterozygous as shown in Figure 12B (left 
panels). This discrepancy can be explained by the possible activation of nonsense-
mediated decay (NMD) leading to rapid degradation of the mutated copy of the 
mRNA but not to the wild type. This possible NMD activation could be due to the 








Figure 12: Chromatograms and gel electrophoresis of the amplified cDNA sequences 
with the identified variants in MPDZ gene of family 1. A) PCR Amplicons of the 
cDNA for the mother, healthy control, and the affected child B) Chromatograms of 
cDNA from the mother, child and a healthy control, showing the wild nucleotide (G) 
at position c.394 of MPDZ gene (indicated by a red arrow). C) Illustrative diagram of 
both copies of MPDZ gene with the variant c.394G>A both in DNA and cDNA 
sequences, explaining the results of the mother and child carrying the variant in a 
heterozygous state in the genomic DNA (Top), while exhibiting only the wild type 
allele (G) due to NMD mechanism (Bottom). 
3.1.4 The c.394G>A Mutation Caused Skipping of Exon 5 of MPDZ cDNA  
 We wanted to further investigate the effect of c.394G>A on mRNA splicing, 






mini-cassette vector used for the analysis of splicing (Figure 13, top). RNA extracted 
from the transfected cells harboring wild type and mutant mini-cassette vectors were 
converted into cDNAs, then they were run on agarose gel electrophoresis showing an 
aberrant transcript with a molecular weight of less than 200 bps compared to the wild 
type which was around 300 bps (Figure 13, bottom left). Upon sequencing both 
bands, the mutant band revealed skipping of exon 5 of MPDZ, while conserving both 
the vector’s exons as expected by the neural network prediction tool. The wild-type 
cDNA showed the presence of exon 5 along with the vector’s exons (Figure 13, 











Figure 13: Illustrative model of the mini-gene analysis protocol. Patterned box depict 
exon 5 and its flanking introns of the subcloned MPDZ gene, black ones depict exons 
13 and 17 of 4.1R gene which was subcloned into pRc/CMV vector. Splicing of the 
wild type cDNA shows the authentic splicing and the inclusion of the three exons 
and that is noticed from the size of the amplified band on the gel (WT). Whereas, the 
mutant cDNA (Mu) shows a smaller band due to cryptic splicing and exon skipping. 
On the right side, the chromatograms represent both splice variants, dashed lines 
separate the joined exons. 
3.1.5 Protein Modeling of the (p.Leu582Val) Variant Indicated Possible 
Disruption to the Protein Structure  
The second variant (c.1744C>G) led to a missense mutation affecting a 
highly conserved residue (p.Leu582Val) (Figure 14A). We therefore, carried out 
molecular modeling experiments to reveal the possible structural effects of this 
mutant. The images in Figures 14B and C were generated using Schrödinger Prime 
and rendered using PyMOL, showing that this variant is located within the MPDZ 






amino acid valine lies between βC and αA of PDZ4, interfering with the conserved 
GLG repeat which is essential for hydrogen bond coordination of the c-terminal 
carboxylate group. Moreover, as already shown in Figure 14A, the site of leucine at 
this position displays evolutionary conservation consistent with the damaging nature 
of the change at that position. 
 
Figure 14: Computational analysis of the missense variant (p.Leu582Val) on MPDZ 
protein A) Multiple sequence alignments for MPDZ protein among different 
Eukaryotic species by Clustal Omega, shows the conservation of amino acid leucine 
among selected Eukaryotic species. B) The rat PDZ4 (wild type) was used to 
generate the image in PyMOL. The conserved GLG loop is shown in red with ball 
and stick representation. The secondary structures (βA, βB, βC, αA, βD, βE, αB, βF) 
are shown with the wild–type Leucine located between βC and αA C) PDZ4 (mutant 
type). The rat PDZ4 structure (PDB ID: 4XH7) was used to generate a model of the 
human PDZ4 domain using Schrodinger Prime. The mutant valine which lies 







3.1.6 Confocal Analysis Revealed that the Pathogenicity of the Compound 
Heterozygous Mutations was not Due to Subcellular Localization Defects 
 To establish whether the pathogenicity of the amino acid substitution 
(p.Leu582Val) is due to the subcellular mislocalization or trafficking defects of the 
mutant protein, HeLa cells were transfected with plasmids harboring the wild type 
and the mutant MPDZ cDNAs (EX-E1329-M10), Accession No.: NM_003829.4, 
tagged with c-Myc-His- from GeneCopoeia (http://genecopoeia.com). In addition, 
although we have shown that the c.394G>A mutation is altering mRNA splicing and 
stability, we wanted to test the alternative possible implication of this variant if the 
protein gets expressed (i.e. generating of a missense mutation at position 
(p.Gly132Ser), we therefore generated this change using the MPDZ cDNA and then 
expressed the mutant in HeLa cells, in similar fashion to the (p.Leu582Val) mutation. 
The two mutants were generated using MPDZ cDNA as a template with the 
following site-directed mutagenesis (SDM) primers;  
MPDZ-G132S-Forward:  5`CAAAAATATGGCCCAGAGTCGCCATGTAGAAG3`  




  In all cases, HeLa cells were co-transfected with GFP-H-Ras as a plasma 
membrane marker, whereas SH-SY5Y cells –neuroblastoma cell lines- were stained 
with Na-K-ATPase plasma membrane marker. Since MPDZ protein is known to co-
localize with synaptic markers and with tight junctions such as claudin-5 at cell 






(Liu et al., 2012), cells were stained with mouse-anti-Myc-tag monoclonal antibody 
(dilution: 1:200; Cell Signaling Technology) and anti-mouse IgG Fab2 Alexa Flour 
555 secondary antibody (dilution: 1:200; Cell Signaling Technology). Confocal 
imaging showed that the localization of the two variants is similar to that of the wild 
type in both types of cells (Figures 15 and 16), thus, excluding the possibility that the 











Figure 15: Comparison of the intracellular localization of the wild type MPDZ 
protein and both mutants in HeLa cells. A) Myc-tagged wild-type (Wt) MPDZ 
protein. B) Myc-tagged (p.Gly132Ser) MPDZ protein. C) Myc-tagged (p.Leu 
582Val) MPDZ protein. They were immunostained with anti Myc antibodies (red). 
Cells were co-transfected with GFP-H-Ras plasmid (green) which localizes at cell 
membrane. Images reveal that the wild-type protein, as well as both mutant proteins 
(red) co-localize largely and similarly with GFP-H-Ras at the plasma membrane, in 








Figure 16: Comparison of the intracellular localization of the wild type MPDZ 
protein and both mutants in SH-SY5Y cells. A) Myc-tagged wild-type (Wt) MPDZ 
protein. B) Myc-tagged (p.Gly132Ser) MPDZ protein. C) Myc-tagged (p.Leu 
582Val) MPDZ protein. They were immunostained with anti Myc antibodies (red). 
Cells were stained with Na-K-ATPase as a plasma membrane marker (green). 
Images reveal that the wild-type protein, as well as both mutant proteins (red) co-
localize largely and similarly with Na-K-ATPase at the plasma membrane, in 







3.2 Endoplasmic Reticulum Retention of Xylosyltransferase 1 (XYLT1) is the 
Underlying Mechanism of some Mutants Causing Desbuquois Dysplasia 
type II 
3.2.1 Clinical Representation of the Studied Patient in Family 2 
The affected male child was born to first cousin parents of Emirati origin. 
There was a history of one stillbirth at full term with similar phenotype. The child 
has one normal sibling and there was no reported history of similar problem in the 
extended family (Figure 17A). The child was conceived through IVF and the 
pregnancy and delivery were at full term and without any notable pregnancy 
complications. However, prenatal ultrasound at five months showed short long 
bones. His birth weight was 2440 gm (M=3.3464, S=0.14602, L=0.3487, =>weight 
z-score: -2.05), length 38 cm (M=49.8842, SD=1.8931, (L=1), =>length z-score: -
6.28) and head circumference 33 cm (M=33.8787, SD=1.1844, (L=1) =>HC z-score: 
-0.74) (http://www.who.int/nutgrowthdb/about/introduction/en/index4.html 
http://www.who.int/growthref/computation.pdf). At birth, the child was noted to 
have short limbs, flat face and small chest. He was evaluated in the Genetic Clinic at 
the age of one month. He had flat face with depressed nasal bridge, long smooth 
philtrum, small mouth with thin lips and short neck. Skeletal survey at one month 
showed short femurs with broadening of the proximal and distal metaphyses, 
bilateral prominence of the minor trochanter ‘mild monkey wrench appearance’, 
shortening of the tibia bilaterally with mild bowing and beaks at the metaphyses, 
shortening and bowing of radius on both sides, the iliac bones were short and broad 
with shallow acetabulum and flat acetabular roof. There was platyspondyly of the 
vertebrae with sagittal clefts. There was shortening of metacarpal and phalangeal 






metacarpal. Based on these findings, a provisional diagnosis of DBQD without hand 
involvement was made. Genetic study of CANT1 gene performed at Inserm 
laboratories (www.idf.inserm.fr) was negative. The affected child was re-evaluated at 
the age of eight years and physical examination showed a weight of 22 kg 
(M=25.4163, S=0.14344, L=-0.5482, =>weight z-score: -1.05), height of 95 cm 
(M=127.2651, SD=5.6480, (L=1), =>height z-score: -5.71) 
(http://www.who.int/nutgrowthdb/about/introduction/en/index4.html 
http://www.who.int/growthref/computation.pdf). He had dysmorphic features 
including flat face with prominent eyes, small mouth, very lax wrist joints and 
interphallangeal joints, and hyperlordosis. However, he had normal developmental 
milestones and was attending normal school. Skeletal survey at 8 years of age 
















Figure 17: Pedigree and radiological images of the DBQD II patient of Family 2. A) 
Pedigree of family 2 with a novel mutation in XYLT1 gene, displaying a first cousin 
couple with the child (III-1) suffering from DBQD II (indicated with an arrow), a 
second normal sib (   ) and a stillbirth with similar phenotypes (   ). B) The 
radiological features of the DBQD type II patient with radiogram of the hip at 8 years 
of age showing the mild monkey wrench appearance only in AP view, note flat 
proximal femoral epiphyses and broad femoral necks. C) Radiogram of the right 
lower limb at 8 years of age showing shortening of the bones, osteopenia and 
beaking of metaphyses which are irregular. D) Lateral radiogram of the spine at 8 
years of age showing hyperlordosis and platyspondyly of L5. Note flaring of the 
metaphyses of the ribs. 
3.2.2 WES and Sanger Sequencing Revealed a Homozygous Single Nucleotide 
Duplication Mutation in XYLT1 Gene 
To exploit next generation DNA sequencing technologies, WES sequencing 
was carried out at Baylor College Genetics Laboratory on the affected child. After 
filtering of the identified variants using the in-house developed softwares, a novel 






identified as the main disease-causing candidate. This variant was re-sequenced in 
our laboratory using Sanger sequencing on the affected child and his parents and was 
found to be homozygous in the affected child and heterozygous in both parents 
(Figure 18A). Bioinformatics analysis indicated that this variant was not present in 
the Exome Variant Server database (http://gvs.gs.washington.edu/gvs/). However, 
two more constitutional variants existed in the same data base (c.2169A>T and 
c.2169A>G) (rs753887357), with protein change p.(Lys723Asn) and p.(Lys723=), 
respectively, this position is pointed with a black arrow as shown in Figure 18B. 
However, the minor allelic frequency of them was 0.0008% and the missense variant 
c.2169A>T, p.(Lys723Asn) was predicted to have a tolerated consequence on the 
protein. In addition, multiple alignments using Clustal Omega showed that the valine 







Figure 18: Chromatograms and alignment of DNA sequence of XYLT1 in Family 2 
with DBQD II affected child. A) The top chromatogram reveals the insertion of (A) 
at exon 10 of XYLT1 gene in a heterozygous state in the father’s DNA. The middle 
chromatogram reveals the same heterozygous insertion in the mother’s DNA and the 
bottom chromatogram shows the homozygous insertion of A in the child. B) Multiple 
sequence alignment of XYLT1 protein illustrating the conservation of the valine at 
position 724 in red box. Arrow indicates the position of the neighboring reported 







The inserted nucleotide, of the current study, is predicted to disrupt the 
translational reading frame of the protein leading to the generation of a frame-shift 
and a termination stop codon at position 733, thus deleting approximately a quarter 
of the XYLT1 protein (http://web.expasy.org) (Figure 19A). 
In silico analyses using MutationTaster showed that the variant is disease 
causing. Furthermore, PolyPhen software predicted the variant to be possibly 
damaging with a score of 0.732. The expected effects of this variant on the size of 
the expressed protein was established by introducing the change into the cDNA in 
mammalian expression vector then expressing the protein in HEK293T cells 
followed by SDS-PAGE and Western Blotting. As predicted the size of the expressed 
protein was smaller (~75 kDa) than wild type (~108 kDa) as shown in Figure 19B, 
confirming truncation of the mutant protein. To further gain insight into disease 
pathogenesis underlying other disease-causing mutations in XYLT1, we generated 
two of the previously reported pathogenic homozygous missense mutations in 
literature (c.1441C>T, p.Arg481Trp) and c.1792C>T, p.Arg598Cys) in XYLT1 
cDNA (EX-E1329-M10) that was purchased from GeneCopoeia (GeneCopoeia, 















Figure 19: The In silico prediction of the variant (p.Val724Serfs*10) on XYLT1 and 
the western blotting analysis of the protein. A) The amino acid sequence of the 
human XYLT1 protein (www.uniprot.org) and the prediction of the variant effect 
(c.2169dupA) on the protein level, showing the generation of a frame-shift at 
position 724 of the amino acid sequence leading to stop after 10 amino acids, the 
predicted size of the truncated protein was around 226 amino acids out of 959 
(www.web.expasy.org), depicted by a blue box. B) The western blotting of XYLT1 
protein from the cellular extract of HEK293T cells transfected with the wild type 
(WT) or mutant (Val724Serfs*10) expression plasmids, the molecular markers on the 
left show the 100, 75 and 58 kDa. The mutant protein’s molecular weight is reduced 
due to the frame-shift mutation and the generation of a truncating stop codon as 
predicted, whereas the other missense variants showed normal molecular weight (108 
kDa). 
The following primers were designed using PrimerX 
(www.bioinformatics.org/primerx/) to generate the required mutations using 






 XYLT1-c.2169dupA-F:  
5'GGGTGATGCCGAAAAAAAGTCTTCAAGATCGCAAG 3' 
 XYLT-c.2169dupA-R:  
5' CTTGCGATCTTGAAGACTTTTTTTCGGCATCACCC3' 
XYLT1-c.1441C>T-F: 5’ GTGGCG CCTGGGAGATTGGCGGATCCCAGAG -3’ 
XYLT1-c.1441C>T-R: 5’ CTCTGGGATCCGCCAATCTCCCAGGCGCCAC-3’ 
XYLT1-c.1792C>T-F: 5' CCTACCTTCTTTGCCTGCAAGTTTGAAGCC 3' 
XYLT1-c.1792C>T-R: 5' GGCTTCAAACTTGCAGGCAAAGAAGGTAGG 3' 
The generated constructs were sequenced by Sanger sequencing to confirm 
the introduction of the desired mutations (Figure 20), and expressed in HEK293T 
cells and their extracts were run on SDS-PAGE and probed with Anti-XYLT1 rabbit 
polyclonal antibody (dilution: 1:500; Sigma). This showed a truncated protein for our 
novel mutant while the other generated missense mutations (c.1441C>T, 
p.Arg481Trp and c.1792C>T, p.Arg598Cys) exhibiting the expected molecular 



















Figure 20: The chromatograms of the XYLT1 cDNA (EX-E1329-M10) plasmid 
mutated by SDM to generate the desired variants, the sites of mutagenesis are 
indicated in red arrows 
3.2.3 Confocal Microscopy Suggests ER Retention as a Cellular Mechanism 
Underlying Several XYLT1 Mutants Causing DBQD Type II 
The subcellular localizations of the generated XYLT1 mutants were 
established by confocal immunofluorescence staining of the transfected HeLa cells, 













rabbit polyclonal antibody (dilution: 1:50; Sigma). As expected, the wild type 
XYLT1 protein localized predominantly to the Golgi apparatus as evidenced by its 
extensive co-localization with the Golgi marker Golgin-97. In contrast, the three 
tested mutants (p.Val724Serfs*10, p.Arg481Trp and p.Arg598Cys) did not co-
localize with this Golgi marker but showed a more extensive reticular pattern 
suggesting ER retention (Figure 21). We therefore, co-stained the expressing cells 
with the well-established ER marker (Calnexin) which showed that the three mutants 
are largely co-localizing with it in contrast to wild type (Figure 22) suggesting 
trafficking defects of the mutant proteins and their retention by ER protein quality 







Figure 21: Immunoflourescence staining of HeLa cells transfected with c-Myc-His-
tagged XYLT1 plasmids. A) The wild type (WT) XYLT1, B) The proband variant 
p.(Val724Serfs*10), C&D are the two reported mutations p.(Arg481Trp) and 
p.(Arg598Cys), respectively. They were probed with rabbit polyclonal anti-XYLT1 
antibodies and merged with the Golgi marker (Golgin 97) showing mis-localization 
from Golgi and retention in ER in all mutants compared to their wild counterpart 









Figure 22: Immunostaining of HeLa cells transfected with the same plasmid and 
generated mutations using anti-XYLT1 antibodies and anti-Calnexin as an ER 
marker to compare the subcellular localization of the wild and mutant proteins in 
cells. A) XYLT1 of WT is predominantly localized in Golgi with some cells showing 
localization in ER (Not shown here) since XYLT1 is synthesized in the ER but exerts 
its catalytic function at Cis-Golgi. However, (B, C and D) all mutants demonstrated 
exclusive localization at the ER. 
To examine the correlation of the two color channels of the tagged-XYLT1 
with the different cellular markers in real image data, co-localization test of the 






graphs, confirming the co-localization of the wild type XYLT1 with Golgin 97 
marker, whereas all the mutants co-localized with Calnexin (ER marker) (Figure 23). 
 
Figure 23: Co-localization test with Pearson and Mander’s scatter-plot and 
correlation coefficients. Plots on the left panel correspond to co-localization of 
XYLT1 with the golgi marker (Golgin 97). Right panels correspond to the co-
localization with the ER marker (Calnexin). Wild-XYLT1 proteins show complete 
co-localization with Golgin 97, resulting in a straight slope with Pearson Coefficient 
(PC) close to 1, compared to calnexin slope (PC<0). While the three mutants show 
full co-localization with the Calnexin (PC=1), and exclusion of the signal with 






3.2.4 XYLT1 Protein is Most Likely Insensitive to Glycosidase Enzymes 
The confocal studies proved the mis-localization of the mutant XYLT1 and 
their retention into the ER compared to the wild type XYLT1 which were shown to 
localize at the Golgi. We therefore wanted to further support this conclusion by 
testing their resistance/sensitivity to glycosidase enzymes. Wild type XYLT1 should 
ideally contain hybrid or complex oligosaccharides moieties, and hence should be 
resistant to Endoglycosidase H (Endo H). Whereas the mutant forms should only 
harbor high mannoses or even simpler forms of oligosaccharides which are sensitive 
to Endo H. We selected two of the glycosidase enzymes that could indicate the 
subcellular localization of proteins. Endo H and peptide N-glycosidase F (PNGase F) 
which can cut most types of glycoproteins. The immunoprecipitated wild type and 
mutant proteins were digested by Endo H which cleaves high mannose and hybrid 
oligosaccharides, but not complex ones. Figure 24A depicts the results of Endo H 
treatments on immunoprecipitated XYLT1 proteins, showing the resistant pattern of 
the wild type and mutant proteins despite the fact that all mutant XYLT1 were 
retained in ER, proved by confocal studies. That could be explained by the fact that 
glycoproteins are resistant to endo H digestion if they have the antennae-like 
structure (core structure), lacking the three linear mannoses (Man1α3Man1α6Man1β) 
shown in Figure 25, even if reactions are driven with high enzymatic concentrations, 
which are essential components that determine the specificity of endo H and endo F2 
enzymes (Trimble & Tarentino, 1991). Thus, we further carried out digestion with 
PNGase F enzyme, which is known to digest the bond between GlcNAc and 
asparagine (Asn), releasing the whole carbohydrate from the protein (Figure 25). It is 
well established that PNGase F can digest complex glycans (Golgi forms) (Freeze & 






Intriguingly, neither the wild-type, nor the mutants showed any shift in the size of 
their protein bands, except for the positive control, which is a reported mutated 
endoglin protein (p.Pro165Leu) with established ER retention and sensitivity to endo 
H (Ali et al., 2011), suggesting resistance of all XYLT1 proteins to PNGase F, 
consequently to all glycosidases (Figure 24B). We concluded that the resistance of 
XYLT1 proteins to PNGase F might be attributed to the location of the N-
glycosylation sites on XYLT1 proteins, and probably if the reaction was left under 
extended incubation times (three days or more) could have shown effect on the 
proteins, however, such conditions would possibly affect the activity of the enzyme 
or the stability of the proteins. Moreover, another explanation for the resistance is 
that XYLT1 protein has only three glycosylation sites, and left with only two in the 
truncated one (p.val724fs*10), and it has been shown that the average size of the 
carbohydrate chain in glycoproteins ranges between 1.5-3 kDa (Freeze & Kranz, 
2010), which in our proteins ranges from 3-9 kDa, and this difference in sizes 
between the cut and the uncut forms cannot be easily demonstrated by western 
blotting. Therefore, it can be deduced from these experiments that the glycosidase 
test may not be applicable to assess the mis-localization of the mutant proteins in the 







Figure 24: The Western blot of the glycosidase tests performed on XYLT1 proteins. A) Endo H assay of the wild-type XYLT1 and the generated 
mutants, all plasmids were transiently expressed in HEK293T cells, immunoprecipitated, then incubated in the presence of Endo H (+) or without 
Endo H (-) for 4 hours at 37 ºC. All proteins showed no susceptibility to Endo H digestion, except for the positive control. B) PNGase F 
susceptibility test of the wild-type and mutant XYLT1 whole cell lysates with the presence (+), or absence (-) of PNGase F for 24 hours at 37 ºC. 






Figure 25: Symbolic structures of the N-linked carbohydrate chains of the glycoproteins showing the specificities of the endo H and 
PNGase F enzymes. The sensitivities are depicted by (+), whereas the resistant forms by (-). Endo H enzyme cannot cleave the core 







3.3 Identification of TSHZ3 and CRTAC1 as Possible Candidate Genes in 
Monogenic Intellectual Disability Syndromes 
3.3.1 Clinical and Molecular Assessment of the Patients in Family 3 
Two daughters born to a Pakistani consanguineous couple were diagnosed 
with microcephaly, severe ID, and muscle hypotonia (Figure 26). The family history 
revealed two other children with similar phenotype. However, we were unable to 
assess them in this study. The first affected child for the couple is a female who is a 
product of normal pregnancy and delivery. Birth weight was 3 kg but no head 
circumference measurements were available as she was born in Pakistan. There were 
no noticeable major neonatal problems. However, in the first few months of life, the 
mother noted that she was very irritable and crying all the time and unable to sleep. 
She was evaluated by a doctor who told the mother that she had small head 
circumference measurement. She was evaluated at Tawam Hospital Genetics Clinic 
at the age of 6 years.  She had severe delay in all milestones with no speech or 
interaction with the mother. She was unable to walk but can sit alone and rocks her 
body forward and backward all the time. However, her weight and height were 
appropriate for her age and no dysmorphic features. Her head circumference at the 
age of 6 years was 46 cm (-5 SD). Neurological examination was normal. She had 
myopia and squint for which she wears glasses. Metabolic screening of very long 
chain fatty acid and phytanic acid as well as microarray analysis were normal.  
Child 2 is the sister of the first patient. She was the product of normal 
pregnancy and delivery but, unfortunately, no birth measurements were available. 
She was similar to her sister in terms of developmental deficiencies. Evaluation at 4 






44 cm (-6 SD). She had severe developmental delay with no dysmorphic features or 
neurological abnormalities. 
We next performed whole-genome SNP genotyping for all the available 
family members (ATLAS Biolabs, GmbH, Germany, www.atlas-biolabs.com). This 
genotyping was performed using the Genome Wide Affymetrix SNP 6.0 genotyping 
assay which detects around 900K SNPs and 900K CNV markers. In addition, 
concurrently we performed WES which was carried out at Sengenics Inc, Kuala 






Figure 26: The pedigree of a highly inbred Pakistani family, the studied branch (family 3) showing consanguineous parents with the two affected 







3.3.1.1 Homozygosity Mapping Identified Several Blocks of Homozygosity 
across the Genome 
 The genome-wide SNP data (calls) for the whole family were uploaded into 
the homozygosity mapper software (www.homozygositymapper.org). The used chip 
was selected, and the analyzed patients’ IDs were entered as cases, whereas the 
healthy were entered as controls. The resulting graphical interfaces were obtained 
from GeneDistiller, and they showed five homozygous stretches of widths ranging 
from 6.8-27.8 Mbs, they were located in chromosomes 7, 9, 12, 14 and 19 (Figure 
27). The largest stretch of 27.8 Mbs was located in chromosome 12. The second 
largest homozygous stretch was mapped on chromosome 19 (22.5 Mbs), followed by 
chromosome 7 which harbored a stretch of 22 Mbs. The fourth stretch was located on 
chromosome 9 (6.8 Mbs) and the smallest stretch of 5.6 Mbs was mapped on 
chromosome 14 as shown in Table 2. In this table, the loci of the homozygous 










Figure 27: The homozygosity map of (Family 3) harboring five homozygous regions 
depicted by red bars. Homozygosity scores are displayed as a genome-wide bar 
chart. Scores higher than 80% of the maximum score are displayed as red bars, 
indicating homozygous regions which are found in the affected, but absent in the 
non-affected members. Smaller decreases of the score within a homozygous region 
are neglected (black bars). Homozygosity is detected in chromosomes 7, 9, 12, 14 
and 19. 
The length of each red bar (homozygous regions) as well as the reference 
SNPs flanking each homozygous region are illustrated in Table 2. 





To (bp) From SNP To SNP 
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5.5 132405157 137911594 rs481158 rs2352478 
16.7 137920895 154663549 rs10272694 rs11768385 
9 6.8 134243090 141071475 rs9328529 rs7863719 
12 
 
13 20371195 33429249 rs4335623 rs10844528 
14.8 33447503 48317832 rs11052596 rs7311030 
14 5.6 25609273 31245971 rs7144438 rs911088 







3.3.1.2 WES Analysis Identified Six Candidate Variants as Potential Cause of 
the Phenotype in Family 3 
 WES analysis was conducted on the two affected siblings to identify novel 
candidate genes that might be responsible for the phenotype in family 3, we 
established an integrated WES data filtering approach aiming first to extract essential 
variants calls such as missense, stop gained, frameshifts and splice-site variants, thus 
excluding intronic and synonymous ones. More than 700,000 variants were obtained 
from the WES data performed on the two affected daughters of family 3 that got 
reduced to 25,000 upon following the filtering criterion. The filtration was conducted 
by Al-Jezawi N.K at the Pathology Laboratory in the UAE University. 
Upon filtering SNP data, only variants encountered within the homozygous 
regions generated by the homozygosity mapper were included in the subsequent 
analysis. After excluding the variants outside the mapped region, the number of 
variants was narrowed down to around 400. Furthermore, the variants which were in 
dbSNPs, 1000 Genome, Exome Variant Server, or ExAC browser or any other 
database were excluded. Additionally, variants with allelic frequency more than 0.01 
were excluded, resulting in decreasing the number to around 250 variants. After we 
excluded the variants not detected among both affected members, the number of 
candidates was narrowed to around 100 variants. The remaining candidates were 
then studied extensively using other bioinformatics tools, assessing their expression 
profiles, cross-checking with published data on their mutations and diseases using 
HGMD, the number reduced to 10-20 candidate genes. The final step was 
performing segregation analysis by Sanger sequencing on all the family members to 








Figure 28: The filtration pipeline used in this study to analyze and prioritize the WES 
data for Family 3 with the number of variants resulting from each step 
Various studies have shown the involvement of several genes in the 
pathogenesis of microcephaly, hence, these genes were cross-checked in both 
patients to look for any damaging variants and were ruled out. For example, in STIL 
gene, one damaging homozygous missense variant (c.3515C>T, p.Ser1172Phe) was 
detected in the patients, however, the gene was excluded because it did not segregate 
with the phenotype among all the family members. Other microcephalic known 
genes (MCPH1, ASPM, WDR62, CDK5RAP2 and CASC5) were as well excluded 
due to their high minor allelic frequencies (GMAF), ranging from 0.22 to 0.99. In 






individuals carrying the same variants in homozygous states. For example, in ASPM, 
one identified variant (p.Tyr2494His) was found to have allelic frequency of 0.999 in 
ExAC database with 60,051 individuals carrying the same variant in a homozygous 
state. Moreover, the remaining genes known to be implicated in microcephaly were 
not detected within the mapped region in our patients. 
The number of potential candidate genes after this filtering analysis was six, 
including variants in OR2A14, ENTPD8, LRRK2, EML2, TSHZ3, and HKR1 genes. 
Segregation analyses using Sanger sequencing of those variants are shown in Table 
3, indicating that the variant in OLFM1 gene can be excluded because it did not 
segregate with phenotype in the family. On the other hand, the variants in the other 
genes segregated and they were all causing missense mutations except for the frame-
shift variant in LRRK2 gene (c.4325_4327delCTT) that led to deletion of alanine at 
position 1442 out of 2527 amino acids. 
Table 3: List of the candidate variants in genes for the clinical phenotypes of 
Family 3  
Chr. Gene Distance 
(Mbs) 
Position  DNA change Protein 
change 
Segregation 
7 OR2A14 22.2 143826206-
143827138 
c.725C>T p.S242F YES 
9 ENTPD8 6.8 140328816-
140335901 
c.505G>A p.G169S YES 
9 OLFM1 6.8 137967089-
138013030 
c.358_359insA p.W129* NO 
12 LRRK2 27.8 40618813-
40763087 
c.4325_4327delCTT AS/S YES 
19 EML2 22.5 46112658-
46148775 
c.2543G>A p.R848Q YES 
19 TSHZ3 22.5 31765851-
31840190 
c.755A>G p.K252R YES 
19 HKR1 22.5 37825580-
37855357 






3.3.1.3 Further Analyses to Test the Candidacy of the Identified Variants  
 In theory only one of those variants could be responsible for the observed 
phenotype and we therefore needed to carry out further detailed analyses to exclude 
or confirm the pathogenicity of individual variants. This included bioinformatics 
analyses, and in some cases functional assays.   
Bioinformatics and in silico Analyses Identified the Variant in TSHZ3 Gene as 
the Strongest Candidate for the Phenotype in this family 
Each identified variant within the candidate genes was evaluated for its 
population allelic frequency in different publically available databases, in addition to 
other bioinformatics tools illustrated in Table 4. 
All the variants in the identified genes were not found in the exome variant 
server (http://gvs.gs.washington.edu/gvs/) and Galax C 
(www.galaxc.sengenics.com), furthermore, their allelic frequencies were very low 
according to ExAC database (www.exac.broadinstitute.org). However, the two 
variants in EML2 and TSHZ3 genes were found in the 1000 Genome Project database 
(www.browser.1000genomes.org), albeit in the heterozygous states. 
The protein effect prediction showed variability according to the nature of the 
variant, and most of the expression profiles of the identified genes were found to be 
abundant in many tissues (Table 4). 
 As already mentioned, we were able to identify a few candidate variants that 
might be responsible for the phenotypes in family 3. While only two candidates 
(TSHZ3 and LRRK2) were among the most reliable, the remaining were excluded, 






of all, ENTPD8 gene which stands for Ectonucleoside Triphosphate 
Diphosphohydrolase 8 enzyme and which has a nucleotidase activity as shown in 
animal models (Fausther et al., 2007), was not considered as a strong candidate 
because we found three normal individuals in genomic databases 
(http://gvs.gs.washington.edu) carrying a damaging variant at position 
(p.Gln166Argfs*88) leading to a truncation of 254 amino acids out of 495, 
additionally, another homozygous damaging variant (p.Leu301Profs*7) was present 
in a homozygous state in 33 normal individuals (www.evs.gs.washington.edu), 
suggesting that this gene  might be dispensable in humans. Besides, the phenotype in 
our patients is mainly neurological, ENTPD8 protein is a liver-enriched enzyme 
responsible for regulating nucleotide concentration extracellulary, and is mainly 
expressed in gastric tissue as shown in Table 4, and therefore this gene is unlikely to 
be implicated in disease primarily affecting the brain. In addition, we would expect 
effects on the gastric system rather than neuronal. 
Moreover, EML2 (EMAP2) gene was excluded because we found five normal 
individuals carrying probably damaging variants in the homozygous states 
(p.Arg558His) and another probably damaging homozygous missense variant 
(c.Leu388Phe) in 145 normal individuals (www.evs.gs.washington.edu). In addition, 
EML2 protein although abundantly expressed as shown in Table 4, has different 
splice-variants with different expression patterns (Lepley, Palange, & Suprenant, 
1999).  EML2 is a microtubule-associated protein that has 65% homology with 
EMAP1, the latter being a strong candidate of Usher syndrome 1a locus, giving this 
group of proteins a possibility of being involved in human diseases in general (Eudy 
et al., 1997). As Table 4 indicates, the identified variant in EML2 gene (c. 2543G>A, 






prediction applied on HKR1 gene, an oncogene that might be involved in 
transcriptional regulation (www.pathcards.genecards.org). As shown in Table 4, 
there exists two possibly damaging missense variants in a homozygous state 
(p.Arg448His and p.Gly28Arg) the first one found in 58 normal individuals out of 
5546 and the second was found in two individuals out of 6410. On the other hand, 
the two frame-shift variants (p.Leu594Hisfs*2 and p.Thr436Argfs*15) reported in 
one and three individuals, respectively were very close to our variant (p.Gly543Glu). 
mRNA of HKR1 was found to be highly expressed in lung tissues and was suggested 
to be involved in lung cancer progression and in mitogen-activated protein kinase 





















ENTPD8 None 0.000008 Disease causing Deleterious/Possibly 
damaging 
Tolerated 2 frame-shift 
variants 
None None YES Colon, small 
intestine, liver, 
pancreatic juice & 
testis 
EML2 None 0.0001 Polymorphism Deleterious/Possibly 
damaging 
Tolerated 2 Missense 
variants 
Het:6 None P Abundant. 
Overexpressed in 
salivary glands & 
peripheral blood 
LRRK2 None NA Disease causing - - 4 Missense 
variants 
None None P Overexpressed in 
Nervous system, 
adrenal gland & 
kidney 
TSHZ3 None 0.00019 Disease causing Tolerated/Probably 
damaging 
Tolerated None Het:1 None YES Abundant, 
overexpressed in 
liver 
HKR1 None 0.00009 Polymorphism Tolerated/Probably 
damaging 
- 2 Missense & 
2 Frame-shift 
None None YES Abundant, 
overexpressed in 
islets of langarhans 
OR2A14 None NA Disease causing Deleterious/Probably 
damaging 
Tolerated None None None YES Highly expressed in 
heart 






OR2A14 gene, on the other hand, encodes a protein responsible for the 
perception of smell. This gene was selected among candidates assumed to play a role 
in the high-altitude pulmonary edema occurring in healthy Chinese who ascend to 
altitudes exceeding 2500 m above sea levels (Yang, Wang, Xu, & Ge, 2017). Despite 
the fact that all the above genes segregate with the phenotype in family 3, their 
expression profiles, protein function and the reported phenotypes make them less 
likely candidates for the phenotype in this family. 
Based on this analysis, we can conclude that Teashirt Zinc Finger Homeobox 
3 Gene (TSHZ3) and Leucine Rich Repeat Kinase 2 (LRRK2) genes are the strongest 
candidates for the phenotypes in family 3. This conclusion is based on the following 
observations. The variant (c.755A>G) described, causes a novel homozygous 
missense mutation (p.Lys252Arg) in TSHZ3. The variant was located in one of the 
biggest homozygous regions (22.5 Mbs). Segregation analysis revealed both affected 
daughters to be homozygous, while parents showed heterozygous states (Figure 29). 
Protein prediction tools such as Mutation Taster showed that the variant was disease-
causing. The variant was absent from the exome variant server and with low allelic 
frequency in ExAC (0.00019). In the 1000 genome project, one individual was found 
to carry the variant but in a heterozygous state. Experimentally, some animal models 
showed loss of viscerocranium upon knockdown of the gene, causing defects in the 
development of the face and brain in zebra fish (Melvin, Feng, Hernandez-Lagunas, 
Artinger, & Williams, 2013). In other studies, some microcephalic patients were 
presented with deletion in TSHZ3 gene (Caubit et al., 2016). Besides, TSHZ3 gene is 
abundantly expressed in brain cortex, which is the main part of the brain affected in 






designed several experiments in an attempt to provide further evidence on its 
responsibility for the observed phenotype in this family. 
 
Figure 29: The chromatogram of DNA sequence of the variant (c.755A>G) in TSHZ3 
gene of Family 3 showing the heterozygous states of the parents and the homozygous 
states of the mutant variant in both affected children. 
Functional Analyses could not Confirm or Exclude the Pathogenicity of 
TSHZ3 Variant  
TSHZ3 is a protein that contains 3 zinc finger motifs in its N-terminal half (25-
25-19 amino acids) and a homeobox domain that binds DNA (71 amino acids) and 






et al., 2011). The identified variant (c.755A>G) lies between two zinc fingers 
responsible for the binding of this protein with Histone deacetylases 1 and 2 
(HDACs 1 and 2) (Figure 30). 
 
Figure 30: Schematic representation of the TSHZ3 protein with its domain structure 
and the relevant binding sites 
I therefore, decided to examine the effects of this variant on binding with 
HDACs. Chromatin immunoprecipitation experiments showed a direct interaction of 
FE65, a protein which binds to the intracellular domain of the beta amyloid precursor 
protein (PP), and TSHZ3 with the promoter region of CASP4 gene. FE65 could 
simultaneously recruit SET, a component of the inhibitor of acetyl transferase, which 
in turn recruits histone deacetylases, to produce a powerful gene-silencing complex. 
Reduced expression of TSHZ3 mediated by genetic or other causes is likely to 
increase CASP4 expression, leading to progression of Alzheimer’s Disease (AD) 







Figure 31: Model showing the network of genes responsible for the suppression of 
CASP4 expression with TSHZ3 playing a pivotal role 
I hypothesized that the identified variant in TSHZ3 which is located between 
two zinc fingers of TSHZ3 protein could alter its suppressive effect on CASP4 gene 
expression by affecting HDACs binding. Therefore, the mutant and the wild type 
TSHZ3 plasmids (Myc-DDK-tagged human TSHZ3) (OriGene, USA) were 
expressed in HEK293T cells, co-immunoprecipitated with Anti c-Myc-Agarose and 
probed with Anti HDACs 1 and 2 to assess the effect of the variant on these protein-
protein interactions. The western blotting assay showed that both the wild type and 












Figure 32: Pull-down assay of both wild type and mutant Myc-tagged-TSHZ3 
proteins shows interaction with HDAC1 and 2. HEK293T cells were transfected with 
either wild type or mutant TSHZ3 cDNA, expression of TSHZ3 and HDACs 1 and 2 
was confirmed by blotting whole cell extract (input). Co-immunoprecipitation of 
TSHZ3 was performed by Anti-Myc slurry, then they were probed with Anti HDACs 
1 and 2 separately, all normalized against GAPDH. 
We also carried out quantification analysis of CASP4 expression in patient’s 
fibroblasts. This was to examine the suppressive function of TSHZ3 on the 
expression of CASP4 gene in order to fully understand the downstream suppressive 
effect of TSHZ3. Therefore, patient’s total RNA was isolated from skin fibroblasts, 
and reverse transcribed using designed TaqMan probes that hybridized on cDNA as 
described in the methods chapter. Comparative quantification was performed on one 
of the daughter’s sample against multiple control samples to assess the change in 






against two house-keeping genes (GAPDH and HPRT). The CT values of the patient 
were measured in comparison with the CT values in multiple healthy controls. The 
expression of CASP4 in the patient sample appeared to be unchanged compared to 
the controls with a p-value of 0.1235 (Figure 33). 
 
Figure 33: Real-time PCR demonstrates that the expression of CASP4 by the 
fibroblasts of patient 2 from Family 3 shows no significant change compared to 
seven healthy controls 
As explained earlier, the second strongest candidate gene was LRRK2. This 
multi-functional domain protein lies in the biggest homozygous stretch in this family, 
spanning a region of 27.8 Mbs. The detected variant (c.4325_4327delCTT) was 
predicted to lead to alanine deletion at position 1442. The protein shows high 
variability of expression in different tissues, however, the highest scored was in the 






and cerebral cortex (www.uniprot.org). The variant was not found in any of the 
investigated databases and it was predicted to be disease causing. However, 
homozygous missense variants were detected in normal individuals, where one of 
them (p.Asn551Lys) was not located within an essential domain. Compared to the 
identified variant in the current study (p.Ala1442del), the deletion was expected to be 
deleterious of a high score (-10.546), cut off value (-2.5) by Provean software 
(www.provean.jcvi.org). 
The identified variant segregated with the phenotype in family 3 as shown in 
Figure 34. 
Our main conclusion from these results is that TSHZ3 gene cannot be 
excluded as a potential cause of the phenotype in family 3.  The results as given in 
Figures 32 and 33 did not support our proposed hypotheses, hence, further 
justification of our conclusion can be achieved by proposing convincing assays that 
will address the issue and can effectively draw a conclusion about the association of 
the identified gene in the studied family. Furthermore, LRRK2 is as well a strong 
candidate gene. However, the knowledge and validation of its attribution to the 
phenotypes are acquired by further functional and experimental analyses that could 
be implemented for the future perspectives of this study. The future research 
objectives could be expanded to include further experimental approaches that can 








Figure 34: The chromatogram of DNA sequence of the variant (c.4325_4327delCTT) 
in LRRK2 gene of Family 3 showing the heterozygous states of the parents and the 









3.3.2 Clinical and Molecular Assessment of the Patients in Family 4 revealed 
CRTAC1 as a Candidate Gene  
In this family, two children affected by intellectual disability, dysmorphic 
features and anorectal anomalies, and two healthy were born to a consanguineous 
Palestinian couple living in the UAE (Figure 35A). The proband is a female (III-4 in 
the pedigree). She is the product of normal pregnancy and lower segment cesarean 
delivery (LSC) due to fetal distress. Her birth weight was 3700 gm. There were no 
significant neonatal problems. She smiled at 2 months and responded to mother. 
However, there was no further progress in development. At 7 months of age, the 
mother noted that the child was hypotonic. Evaluation at 1 year of age showed a 
dysmorphic child with hypotonia and head lag, joined eyebrows, depressed nasal 
bridge, short nose, long smooth philtrum, thin upper lip with downturning corners, 
overlapping toes. She was unable to sit or bear weight on her leg. She had difficulty 
in swallowing and was on pureed food only. No seizures were reported. She had a 
similarly affected 12 years old brother (III-1 in the pedigree). He had anorectal 
malformation diagnosed at birth which was operated on. He is severely intellectually 
disable with similar dysmorphic features like his affected sister.  
To exclude CNVs or any other structural aberrations in the proband’s 
chromosomes, CGH microarray was performed at Sengenics, Kuala Lumpur, 
Malaysia (www.sengenics.com) on the patient (III-1). The result of CGH was 
negative. As a next step, SNP genotyping for the whole family was performed at 
ATLAS Biolabs, GmbH, Germany (www.atlas-biolabs.com) using Genome Wide 
Affymetrix SNP 6.0 genotyping assay. WES was performed at Sengenics, Kuala 






3.3.2.1 Homozygosity Mapping Identified Blocks of Homozygosity across the 
Entire Genome 
The genome-wide SNP data (calls) for the whole family were uploaded in the 
homozygosity mapper software (www.homozygositymapper.org). The used chip was 
selected, and the analyzed patients’ IDs were entered as cases, whereas the healthy 
were entered as controls. The resulting graphical interfaces were obtained from 
GeneDistiller, and they showed 11 significant homozygous stretches located in 
chromosomes 4, 5, 7, 8, 10, 12, 13, 14, 15, 16 and 18. The largest stretch was located 










Figure 35: The pedigree and the homozygosity map of family 4 A) The pedigree 
shows two siblings affected by ID and dysmorphic features and two other healthy 
siblings, for a consanguineous parent. B) The homozygosity map shows the 
homozygosity scores displayed as a genome-wide bar chart. Scores higher than 80% 
of the maximum score are displayed as red bars, indicating homozygous regions 
which are found in the affected, but absent in the non-affected members. Smaller 
decreases of the score within a homozygous region are neglected (black bars). 








3.3.2.2 WES Analysis Identified Variants in Six Candidate Genes for the 
Phenotype in Family 4 
After performing genome-wide SNP genotyping on all family members, the 
generated homozygosity map showed homozygous regions across the genome 
inherited from common ancestors. We applied WES on the affected siblings, the 
previously applied WES pipeline filtering suggested the candidacy of six genes 
harbouring biallelic variants within the long runs of homozygosity in the patients, 
segregating with the phenotypes. Table 5 lists the candidate genes and their 














Table 5: A list of all candidate genes which are likely associated with the clinical 



























7 GIMAP2 10 148258161
-
158279130 
c.53C>A p.Ala18Asp NO 
7 PDE1C 13.5 20792107-
34334957 
c.280T>C p.Ser94Pro NO 




















3.3.2.3 Sanger Sequencing Revealed a Possible Deleterious Segregating Missense 
Variant in Cartilage Acidic Protein 1 (CRTAC1) Gene 
 Sanger sequencing performed on all the family members for the listed 
candidate genes confirmed WES findings for CRTAC1 gene exclusively. Both 






both the father and the mother were carriers. Child 2 (healthy sib), was homozygous 
to the wild type (GG), while child 3 (healthy sib) was heterozygous (Figure 36).  
 
Figure 36: The chromatograms of the DNA sequence of the variant (c.1798G>A) in 
CRTAC1 gene. The father (F) and the mother (M) show    heterozygous pattern (R), 
while the affected Children (C1, C4) are homozygous to the variant (AA). Children 2 
and 3 (C2, C3) are healthy sibs showing wild type (GG) and heterozygous (R), 
respectively. 
The variant was predicted to be disease-causing and deleterious by Mutation 
Taster and SIFT softwares, respectively. It was also predicted to be damaging by 
FATHMM with a score of (-2.99). Furthermore, segregation analysis for all the 
remaining variants showed no linkage with the phenotypes among all family 






is located in chromosome 10 and is overexpressed in in bladder, artery, tibia, CSF, 
cartilage, synovial fluid, brain cortex and fetal brain (www.genecards.org). The 
variant was absent in the exome variant server with no damaging variants existing in 
homozygous states in CRTAC1 gene. However, one homozygous variant existed in 
ExAC database with very low allelic frequency (0.00006). In the exome variant 
server, one probably damaging variant (p.Val569Met) existed in 3 individuals out of 
6216. Figure 37 shows the conserved nature of glutamate (E) among multiple species 
at the identified position. 
 
Figure 37: Multiple species alignment showing the conservation of the wild type 
amino acid (E) observed in CRTAC1 gene 
 In conclusion, both the bioinformatics and segregation analyses provided 
moderate evidence that the variant identified in CRTAC1 gene could be causal to the 
phenotypes of the affected children in family 4. In order to elucidate whether the 
gene is directly involved in the pathogenesis of the disease, experimental, animal or 
human models (well-phenotyped patients) should be carried out. 
To further confirm the pathogenicity of the identified variant in CRTAC1 
gene, we have submitted those variants to the gene matcher data base 






researchers and clinicians in order to find other families around from other parts of 
the world who share similar phenotypes and genes. We also submitted TSHZ3 and 

























Chapter 4: Discussion 
In this study we have performed genomic and cellular experiments in order to 
establish the molecular and cellular mechanisms of autosomal recessive disorders in 
families residing in the UAE. It is expected that such autosomal recessive disorders 
are caused by biallelic mutations in genes encoding proteins involved in vital 
functions in human. These disorders appear to be Mendelian and therefore could be 
identified and proved by different genetic analyses. 
Robust and state of the art genetic approaches have been applied here in an 
attempt to elucidate mechanisms, include, or exclude candidate genes. As 
hypothesized, consanguineous and highly inbred families offer tremendous potentials 
to discover novel causative genes and mutations believed to be responsible for 
recessive phenotypes, in a way to achieve precise diagnosis and assist in integrating 
preventive programs. 
4.1 Compound heterozygous variants in the multiple PDZ domain protein 
(MPDZ) cause a case of mild non-progressive communicating 
hydrocephalus 
 Hydrocephalus is caused by the build-up of CSF in the brain ventricles 
leading to increase in pressure on the brain tissue. CSF is produced in the choroid 
plexus and flows through the brain chambers and the sub-arachnoid space. If this 
flow is blocked or the absorption of excess CSF is hindered, hydrocephalus occurs 
(Rekate, 2008). Communicating (non-obstructive) hydrocephalus refers to the 
accumulation of CSF despite the absence of blockage; this could be explained by the 
impairment of CSF reabsorption by the arachnoid granulations. On the other hand, 






blockage in CSF flow. Moreover, hydrocephalus is classified into acquired, 
occurring at any age due to injuries, stroke, tumors, meningitis or hemorrhages, and 
congenital which is present at birth, mainly due to genetic factors (Tully & Dobyns, 
2014). Furthermore, progressive hydrocephalus refers to increased intracranial 
pressure that might need surgical intervention or non-progressive if the 
hydrocephalus is not accompanied with any neurosurgical treatments (Kirkpatrick, 
Engleman, & Minns, 1989). The reported child of family 1 in this study has 
congenital communicating hydrocephalus with no associated abnormalities and near 
normal development. The hydrocephalus was non-progressive and did not require 
shunting. The affected child was found to have compound heterozygous variants in 
the MPDZ gene. A single homozygous CH-causing mutation in this gene has been 
recently reported in two individuals from two unrelated Saudi Arabian families. The 
phenotype in these previously reported families is much more severe compared to the 
patient described in here. In addition to a severe progressive hydrocephalus requiring 
shunting, other abnormalities were reported in the affected individuals including 
simplified gyration pattern in all of them, and coloboma with congenital heart disease 
in one of them. In addition, there were two still births presumably due to CH in one 
family and six CH cases in the second extended family. The cognitive outcome of the 
two long term survivors in Al-Dosari et al. (2013) correlated with the speed of 
neurosurgical intervention initiation after birth (Al-Dosari et al., 2013). Moreover, 
five hydrocephalic stillbirths from three unrelated families were identified. Three 
probands were genetically tested to find null mutations in MPDZ gene. Medical 
termination was achieved to all fetuses except for one in whom the child died from 
severe hydrocephalus (Saugier-Veber et al., 2017). Table 6 compares and lists all the 




Table 6: The reported MPDZ mutations in patients with congenital hydrocephalus 
DNA Change Protein Change No. of 
Patients 
Origin Phenotypes Ref. 
c.628C>T p.(Gln210*) 1 Saudi Severe congenital 
supratentorial hydrocephalus, mild 








c.1291_1294del p.(Val431Metfs*14) 2 sibs Senegalese Massive hydrocephalus (Saugier-Veber 
et al., 2017) 
c.533+1G>T Frame-shift 2 - Foetal macrosomia with 
severe isolated ventriculomegaly 
(Saugier-Veber 
et al., 2017) 
c.2248C>T p.(Arg750*) 3 sibs - Recurrent hydrocephalus (Saugier-Veber 







Predicted:  p.Gly132Ser 
Experimentally shown 




1 Emirati Congenital non-progressive 
communicating hydrocephalus with 








The null mutation reported by Al-Dosari et al. (2013), led to a truncation of 
12 domains out of 13, abolishing most of the interactions with other proteins and 
effectively leading to null effects and complete loss-of-function of the MPDZ 
protein, which possibly had rendered the affected members severely hydrocephalic. 
However, in our study, we detected a splice site and missense variants that might 
provisionally affect domains (L27 and PDZ-1, as well as PDZ4, respectively). 
 MPDZ protein has many possibilities of interactions due to its multiple-
domain structure. Each domain is highly conserved among species and each is made 
up of six beta sheets and two alpha helices (Figures 14B, C). Furthermore, the 13 
PDZ domains are >50% homologous in rat MUPP1/MPDZ protein (Ullmer, 
Schmuck, Figge, & Lübbert, 1998). I present in Figure 38 the alignment of the 13 
domains in human MPDZ, showing homology in the preserved GLG loop, as well as 
other locations. This loop lies between βA and βB sheets. It functions as a 
coordinator for hydrogen bond of the C-terminal carboxylate group of the binder 
protein. Another important domain in MPDZ is the hydrophobic pocket, which lies 
between βB and αB, constituting the canonical binding sites for MPDZ. Opposite to 
this binding groove, at about 30 residues C-terminal extension of the PDZ domain lie 






Figure 38: The alignment of the 13 PDZ domains in MPDZ protein of human, indicating the homologous regions in colored boxes showing a 






The change from leucine (non-polar and bulkier side chain) to valine (non-
polar with smaller side chain) at position 582 is predicted to be disturbing the GLG 
loop (Figure 14C). Despite the fact that glycine is neither at the GLG loop nor within 
the hydrophobic pocket, it is predicted that the reported variant c.394G>A is in an 
acceptor splice site region, leading to the generation of a stop codon, hence 
truncating the majority of the protein domains, leaving the protein with only L27 
domain.  
The variant (c.394G>A) lies between L27 and PDZ1, PDZ-1 domain is 
known to enhance binding of other PDZ domains. For example, PDZ-2 domain of 
Syntenin (a PDZ domain that functions as an adaptor) binds neurexin, ephrin-1 and 
syndecan only when paired with PDZ-1 (Hui, Xing, & Bader, 2013) (Grootjans, 
Reekmans, Ceulemans, & David, 2000). Moreover, Grootjans et al. (2000) showed 
that PATJ, a protein involved in cell polarity and a mammalian paralogue of MPDZ, 
has a PDZ-1 domain linked to L27 domain. When they decreased both domains in 
mammalian cell culture, it resulted in disassembly in tight junctions. Strikingly, they 
had to be linked together for PATJ to function properly (Grootjans et al., 2000). 
On the other hand, this variant has been predicted to cause a splice-site 
aberration. Indeed, the absence of the mutated copy of mRNA that was revealed by 
sequencing the cDNA for the mother and child suggested an NMD mechanism which 
is consistent with the prediction of the Neural Network prediction tool. Following 
that, we had to investigate the effect of that variant on MPDZ expression by 
quantifying mRNA using real time PCR. Unfortunately, MPDZ is expressed at very 
low levels in the hematopoietic lineages (https://www.ncbi.nlm.nih.gov/unigene). 






enabling further characterization of the mutant. However, tissue sources expressing 
high amounts of MPDZ such as skin fibroblasts could not be obtained from the 
patient. Consequently,  mutant and wild mini-gene constructs were designed to 
analyze splicing variants (Desviat, Perez, & Ugarte, 2012), in order to verify the 
effect of the variant (c.394G>A) on mRNA splicing and to reveal the possible 
disease mechanism. Upon sequencing cDNAs from the resulting constructs, they 
revealed the actual adjoining of the exons in the wild-type, while skipping of exon 5 
of MPDZ gene within the mutant. This is explained by the fact that the variant 
(c.394G>A) is located at the first nucleotide of exon 5 which was predicted to cause 
a splice-site aberration (Figure 13). 
 With reference to the second variant of the compound heterozygous 
mutations, the amino acid leucine, which is substituted at position (c.1744C>G), is 
also conserved at that position among multiple species (Figure 13A). It lies between 
βC sheet and αA of PDZ-4 domain. This change could be disease causing/probably 
damaging according to Mutation Taster and PolyPhen (score 1.0), respectively. It has 
been shown that binding of PDZ-5 domain of GRIP (Glutamate receptor interacting 
protein) to its receptor GluR2 failed to occur in the absence of PDZ-4 domain, 
indicating its role in the proper folding of the other domain (Hung & Sheng, 2002). 
Although the change in our variant did not take place in any of the canonical binding 
sites of MPDZ, function of PDZ-4 was not only restricted to such binding, rather 
PDZ-4 was shown to be involved in the direct binding of PDZK1 (a MPDZ domain-
containing protein in hepatocytes which controls the expression and localization of 
HDL receptors) to the inner leaflet of the cell membrane. This binding was not due to 







It was assumed in this study that since MPDZ localizes at cell-cell adhesion 
sites and is involved in regulating permeability, mutations in this protein would 
disrupt this localization. Hence, alteration in CSF secretion would result in 
hydrocephalus. After performing confocal microscopy on the wild type and mutant 
plasmids, we observed no difference in the subcellular localization of either mutant 
compared to the wild type. That was confirmed in HeLa as well as SH-SY5Y cells, 
the latter cell line was used because it is a human cell line derived from a patient with 
neuroblastoma and is used as a model for neuronal function and differentiation (La 
Quaglia & Manchester, 1996). Therefore, we assume that the pathogenesis of these 
missense changes is not due to trafficking defects; rather it could be due to disruption 
or complete loss of the protein function or an essential protein-protein interaction. In 
addition, all the reported variants in MPDZ gene listed in Table 6 have resulted in 
more severe types due to the formation of null mutations, whereas the variants 
identified in the current study might have retained partial function leading to less 
severe phenotypes.  
In conclusion, the identified compound heterozygous variants detected by 
whole-exome sequencing and confirmed by Sanger sequencing in the affected child 
are the most likely cause of his CH. The deleterious effects of the two variants have 
been illustrated either experimentally or by bioinformatics tools. The clinical 
presentation is consistent with CH which we strongly argue to be caused by the 






4.2 Endoplasmic Reticulum Retention of Xylosyltransferase 1 (XYLT1) Mutants 
Underlying Desbuquois Dysplasia type II 
DBQD is a rare disease which is part of a group of disorders which are 
characterized by multiple joint dislocations and therefore given the term ‘The 
multiple dislocation group of disorders’. The main features of these bone dysplasias 
include flat face with prominent eyes, joint laxity with dislocations of large joints, 
and growth retardation (Alanay & Lachman, 2011). Radiologically, it is 
characterized by short long bones with a monkey wrench appearance of the proximal 
femora and advanced carpal and tarsal ossification. The presence of additional hand 
anomalies (extra ossification center distal to the second metacarpal, delta phalanx, 
and bifid distal phalanx of the thumb) in some patients has led to its classification 
into DBQD type I (with additional hand anomalies) and DBQD type II (without such 
anomalies) (Faivre et al., 2004) (Kaissi, Radler, Klaushofer, & Grill, 2009). The 
patient in this report was classified as DBQD type II, as he had most of the clinical 
and radiological features of DBQD including the mild monkey wrench abnormality 
of the femora, but the typical hand anomalies seen in type I were absent. WES 
analysis on this child revealed a novel variant in XYLT1 gene (c.2169dupA) resulting 
in truncation (p.Val724Serfs*10) of the xylosyltransferase enzyme. This variant, 
segregated with the phenotype among the family members and is expected to result 
in a truncated protein, and immunofluorescent experiments demonstrated mis-
localization resulting in a loss of XYLT1 function which is the first limiting step 
among a series of enzymes (β1,4 galactosyltransferase1, β1,3 galactosyltransferase2, 
and β1,3 glucosyltransferase 1) that are spatially related in glycosylation at the Golgi 







Figure 39: Biosynthesis of Proteoglycans (PGs) and the enzymes involved in the GAG (Glycosaminoglycan) chains assembly. 
XYLT1 initiates the addition of xylose followed by galactosyltransferases adding galactose, then glucosyltransferase adding 




During bone development, chondrocytes are surrounded by PG rich matrix 
that assists in their maturation, as well as the initiation of endochondral bone 
formation. Defects in chondrocytes formation can lead to skeletal phenotypes (Eames 
et al., 2011). PGs synthesis is initiated by XYLT1 enzymes through adding GAG 
chains covalently, giving PGs the physiochemical features to withstand compression 
forces (Schreml et al., 2014). Polymorphisms in XYLT1 gene were found to correlate 
with decreased GAG levels (Ambrosius, Kleesiek, & Götting, 2009). 
XYLT1 enzymes are expressed in chondrocytes during fetal development, 
and in children during mineralization of osteoblasts (Prante, Kuhn, Kleesiek, & 
Götting, 2009), aside from that, they localize at cis-Golgi where they exert their 
catalytic function (Mis et al., 2014). Furthermore, reduction in the activity of XYLT1 
was associated with a decremental growth of vertebral bones in animal models  
(Morriss Jr, Fitzgerald, & Riddle, 1985). On the other hand, mutations in the other 
enzymes involved in this pathway lead to other developmental disorders. For 
example, mutations in B4GALT7 gene were found in patients affected by Ehlers-
Danlos syndrome (Faiyaz-Ul-Haque et al., 2004), as well as patients affected by 
short stature, hypermobility and hypotonia (Salter et al., 2016). Mutations in 
B3GALT6 gene were as well recovered in Ehlers-Danlos syndrome patients (Malfait 
et al., 2013) and Al-Gazali syndrome (Al Gazali, Al Talabani, Mosawi, & Lytle, 
1994; Sellars, Bosanko, Lepard, Garnica, & Schaefer, 2014). Moreover, damaging 
mutations in B3GAT3 gene were detected in patients with Peters Plus syndrome 
(Lesnik Oberstein et al., 2006). All these syndromes included skeletal dysmorphisms 




The current functional study confirmed the mis-localization of the mutant 
enzyme and its retention into the ER (Figures 21-23). This result was also noticed for 
a previously reported missense mutation p.(Arg481Trp) introduced in this study and 
which coincides with the finding of Schreml and colleagues done on patients’ 
fibroblasts showing loss of predominance of mutated XYLT1 in Golgi. Likewise, the 
second generated missense mutation p.(Arg598Cys) which is located in the 
xylosyltransferase domain and which was expected to be damaging being replaced 
by a neutral amino acid (Bui et al., 2014), revealed the apparent retention of the 
enzyme in the ER.  It has been shown that retention in the ER is involved in the 
cellular mechanism of several musculoskeletal abnormalities including Robinow 
syndrome (Ali et al., 2007), and acromesomelic dysplasia-type Maroteaux (Hume et 
al., 2009). To further confirm the retention of the mutant XYLT1 in the ER as was 
shown by confocal studies and quantitative co-localization tests, we analyzed the 
susceptibility of our glycoprotein to Endo H and PNGase F enzymes. Both of the 
mutant and the wild types showed resistance to both enzymes (Figures 24A & B). 
Glycoproteins are resistant to Endo H if they have complex oligosaccharides or 
antennae-like structures (core structure) lacking the three linear mannoses 
(Man1α3Man1α6Man1β (Trimble & Tarentino, 1991). In our case, the mutant 
XYLT1 proteins were shown to be retained into the ER, and complex glycosylation 
does not take place before the medial to trans-Golgi network (TGN) (Freeze & 
Kranz, 2010). However, the wild type XYLT1 proteins were resistant to endo H 
because they resided in the Golgi and must have got glycosylated to higher complex 
forms. We hence thought that this assay might not be suitable to confirm the effect of 
the mutation on the mis-localization, so we decided to further confirm that by 




innermost (GlcNAc), leaving only asparagine attached to the core protein, it can cut 
high mannose, hybrid, complex and multi-sialylated glycoproteins, even, tetra-
antennary and sulfate containing residues (Roth, Yehezkel, & Khalaila, 2012). 
However, glycoproteins with α 1,3 fucose residue attached to the innermost fucose 
bond are known to be resistant to PNGase F, they are found in plants and insects 
(Wilson, Harthill, Mullin, Ashford, & Altmann, 1998), similarly, it has been also 
detected in a few human glycoproteins such as transferrin (Fabini, Freilinger, 
Altmann, & Wilson, 2001). Additionally, two α 1,3 fucosyltransferase genes (FUT10 
and FUT11), although not verified experimentally, have been detected in human 
genome by comparison (Becker & Lowe, 2003). Nevertheless, fucosylation at 
position α 1,3 probably was not the reason for this resistance, since all the mutant 
forms were proved to be localized in the ER, rather we attributed that to the location 
of the N-glycosylation sites on XYLT1 proteins, and probably if the reaction was left 
under extended incubation times (three days or more) could have shown effect on the 
proteins, because PNGase F is a large enzyme (37 kDa) and its size can sometimes 
hinder its accessibility to certain proteins. However, such conditions would possibly 
affect the activity of the enzyme or the stability of the proteins. Moreover, another 
explanation for the resistance is that XYLT1 protein has only three glycosylation 
sites (slightly glycosylated), and left with only two in the truncated one 
(p.val724fs*10), and it has been shown that the average size of the carbohydrate 
chain in glycoproteins ranges between 1.5-3 kDa (Freeze & Kranz, 2010), which in 
our proteins ranges from 3-9 kDa, and this difference in sizes between the cut and the 
uncut forms cannot be demonstrated by western blotting (Figure 24).  
In conclusion, the glycosidase sensitivity/resistance assay was not the test of 




XYLT1 enzyme is composed of two domains, the glycosyltransferase domain 
(amino acids: 328-581) and the xylosyltransferase domain (amino acids: 613-794). 
Thus, the truncation here will clearly omit most of the xylosyltransferase activity of 
the enzyme (Bui et al., 2014). Figure 40 represents the position of our proband 
variant (c.2169dupA, p.(Val724Serfs*10)) as well as all the previously reported 
mutations relative to both domains. Bioinformatic analysis performed on our proband 
predicted the termination to occur at position 732 deleting around 227 amino acids at 
the c-terminal end of the protein including an important motif (745DWD747) which 
was shown to be essential for the activity of XYLT1 (Götting, Kuhn, Zahn, 
Brinkmann, & Kleesiek, 2000), unlike the N-terminus of XYLT1 which was proved 
not to be involved in the function of UDP or heparin sulfate binding. Moreover, 20% 
of the N-terminal region of the enzyme is not necessary for it to function, i.e, from 
amino acid 1 to 260 of XYLT1, as truncation studies revealed. A 70% reduction of 
the enzymatic activity was noticed when amino acids between 260 and 266 were 
deleted, whereas, 91% loss resulted when Cys at position 276 was mutated. Although 
the exact binding site to heparin is not yet determined, the presence of basic clusters 
of amino acids throughout the whole enzyme is essential for its binding to its 
substrates, and these clusters could be noticed at P721KKVFKI727, which has been 
speculated to be responsible for the loss of activity due to induction of 
conformational changes rather than reduced or inhibited binding to heparin (Müller 
et al., 2006). Moreover, XYLT1 has three N-glycosylation sites; N-226, N-421, N-
777. Loss of the last glycosylation site due to truncation might affect the protein’s 






Figure 40: Schematic presentation of the 12 exons of XYLT1 protein indicating the positions of all the previously reported mutations in DBQD II 
patients on the protein domains represented by patterned bars. (Red refers to the nonsense and frameshift mutations and black refers to the 
missense mutations), (The asterisk points at our proband variant) domains represented by patterned bars.  
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Schreml and colleagues studied XYLT1 expression in patient’s fibroblasts of 
the variant (c.1441C>T, p.(Arg481Trp)) and found that there was no apparent 
reduction in the enzyme expression. However, it led to defects in PG synthesis. On 
the other hand, the variant (c.1290-2A>C) which affected a donor splice-site in two 
unrelated Turkish families exhibited reduction in XYLT1 expression as well as a 
decrease in chondroitin-sulfate PG (CS-PG). Similarly, the Mauritian family with 
one affected individual with the variant (c.439C>T, p.(Arg147*), revealed a 
reduction in CS-PG as well as XYLT1/2 expression, the latter being a paralog to 
XYLT1 with high degree of homology (Bui et al., 2014). Currently, few patients 
have been identified with homozygous mutations in XYLT1 gene segregating with 
DBQD type II among different ethnicities, with nonsense, missense and splice-site 
mutations (Table 7). However, the underlying cellular mechanisms of disease of 
most of these mutations have not been fully elucidated. 
In summary, we have identified a novel disease-causing XYLT1 variant 
(c.2169dupA, p.(Val724Serfs*10)) and presented data to suggest that retention of 
variant XYLT1 protein is the mechanism for decreased XYLT1 activity of several 
mutations in this gene. Hence, we propose that a decrease in mature GAGs might be 
the underlying disease mechanism for the disease, and this finding might be 
considered a functional test in DBQD II patients associated with missense mutations 






Table 7: The genetic background of all the reported DBQD II affected patients 




Origin Consanguinity Ref. 
c.1792C>T p.Arg598Cys 2 sibs 24, 20 Tunisian Yes (Bui et al., 2014) 
c.439C>T p.Arg147* 1 14 Mauritian Yes (Bui et al., 2014) 
c.276dup p.Pro93Alafs*69 1 23 Belgian Yes (Bui et al., 2014) 
c.1588-3C>T Exon skipping 1 5.5 Turkish Yes (Bui et al., 2014) 
c.1290-2A>C Exon skipping 1 13 Turkish Yes (Bui et al., 2014) 
c.1290-2A>C Exon skipping 1 1 Turkish Yes (Bui et al., 2014) 
c.1441C>T p.Arg481Trp 2 sibs 16, 18 Turkish Yes (Schreml et al., 2014) 












3.3 Mb del) 
0-alleles 1 sib, 3 
stillbirths 
5 weeks Dutch No (van Koningsbruggen et 
al., 2016) 






4.3 Possible Involvement of Variants in TSHZ3, LRRK2 and CRTAC1 Genes in 
Monogenic Intellectual Disability  
 Intellectual disability (ID) is the most widely common neurodevelopmental 
disorder characterized by intellectual and adaptive behaviors. It can be syndromic, 
associated with other medical problems, or non-syndromic presented without any 
other abnormality. The etiology of ID remains unknown in 30-50% of cases, yet, in 
other cases they could be caused by genetic and/or environmental factors (Daily, 
Ardinger, & Holmes, 2000). Because of the heterogeneous nature of ID, the number 
of genes involved has been continuously increasing due to the great advances in 
genotyping, DNA sequencing and bioinformatics technologies. Depending on the 
genes involved and the nature of the mutation, phenotypes in ID syndromes vary 
from mild to profound. In addition, it is not uncommon to find different mutations in 
the same gene responsible for the syndromic or the non-syndromic types (Chiurazzi 
& Pirozzi, 2016). Until November 2013, a list of 925 genes has been confirmed to 
cause developmental disorders (Wright et al., 2015), with many more discovered 
thenceforth 
 A neurodevelopmental disorder that has been genetically analyzed in the 
current study is microcephaly. Microcephaly is a recessive autosomal disorder which 
is characterized by small brain size (mainly the cortex) with normal architecture 
(Woods, Bond, & Enard, 2005), the occipitofrontal circumference (OFC) is reduced 
by at least 4 standard deviations. Autosomal recessive primary microcephaly 
(MCPH) is generally, with exceptions, presented with normal height and weight as 
well as normal chromosomal analysis (Mochida & Walsh, 2001). MCPH is 
diagnosed prenatally and is non-progressive. On the other hand, secondary 




factors that distinguish the primary type from the secondary, for example, primary 
microcephaly most often occurs in consanguineous families, and in families with 
history of multiple pregnancy losses, as well as early onset of microcephaly, and 
normal early developmental milestones, all characterize the primary type (Qazi & 
Reed, 1973). The incidence of MCPH ranges from 1.3-150/100,000 births depending 
on levels of consanguinity (Kaindl et al., 2010). Neuronal progenitor cells divide into 
symmetrical (cells dividing parallel to the neuroepithelium) or asymmetrical 
orientations (cells dividing perpendicular to the neuroepithelium), the timing of such 
divisions is critical during development (Finlay & Darlington, 1995). In addition, 
disruption of the plane cell cleavage leads to microcephaly (Haldipur, Sivaprakasam, 
Periasamy, Govindan, & Mani, 2015). Until January 2015, twelve loci have been 
mapped in microcephalic patients harboring the following genes; ASPM, CENPJ, 
STIL, CEP135, CEP152, ZNF335, PHC1, Microcephalin, WDR62, CDK5RAP2, 
CASC5, and CDK6. The mechanisms of most of the genes are; disturbed mitosis, 
abnormal chromosomal condensation, loss of DNA repair and microtubule dynamics 
(Faheem et al., 2015).  
 The more severe ID forms typically occur early in life, and are usually 
accompanied with dysmorphic features; these include malformations, deformations 
and dysplasias. The effect of single gene mutations is often represented by 
syndromes such as dysmorphisms (Reardon & Donnai, 2007). If the 
dysmorphological pattern could not be matched to any of the known syndromes it 
can lead to a serious diagnostic challenge, or it can be inaccurately referred to as a 
novel syndrome. The discovery of novel genes implicated in several disorders has 
accelerated recently, similarly, in the setting of dysmorphology. In 2016, a 




individuals suffering from dysmorphic features, facilitating gene discovery among 
geneticists (Shaheen et al., 2016).  
 The family here shows obvious features of autosomal recessive inheritance as 
the pedigree shows in Figure 26. Homozygosity mapping implicated homozygous 
regions on chromosomes 7, 9, 12, 14 and 19 with one of them presumed to be 
harboring the causative gene. In addition, bioinformatics tools supported their 
involvement in the disease. Furthermore, it was shown that one of the most important 
factors determining the implication of a gene in a phenotype is its transcriptional 
profile by using different databases which collected the mRNA data from expression 
experiments (Chiurazzi & Pirozzi, 2016), such databases are listed in Table 1. The 
expression profiles of the candidate genes of this family in Table 4 were retrieved 
from gene cards database (www.genecards.org), it is obvious that most of the 
candidate genes are abundantly expressed in most tissues, being overexpressed in 
certain tissues more than others. However, EST (Expressed Sequence Tags) profiles 
available at (https://www.ncbi.nlm.nih.gov/UniGene/ESTProfileViewer.cgi) showed 
that all the genes are expressed in brain at different levels, except for ENTPD8 gene, 
which is mainly expressed in gastrointestinal tissues. Although we should expect that 
most genes impairing cognition and affecting brain’s architecture should be 
reasonably expressed in brain, it has been shown that the majority of syndromic ID 
genes were expressed highly in other tissues as well (Chiurazzi & Pirozzi, 2016). 
 Several genes lay within long homozygous stretches of widths more than 22 
Mbs, with TSHZ3 gene being there and therefore it was considered a strong 
candidate. Although the identified variant in this gene (c.755A>G, p.Lys252Arg) 




alternative amino acids. It is, however, possible that it could affect binding of TSHZ3 
protein to the silencing complex; especially that the variant lies near the N-terminal 
zinc fingers known to be responsible for the HDACs 1 and 2 binding (Kajiwara et al., 
2009). Moreover, the identified variant (Arg) lies within the sequence 
(PRRWSKPRKR) which was predicted to be a nuclear localization signal (NLS) by 
cNLS Mapper (Kosugi, Hasebe, Tomita, & Yanagawa, 2009). The functional assays 
were designed to prove the effect of this variant on the protein’s ability to bind 
HDACs 1 and 2 using western blotting. HEK293T cells were transfected with 
TSHZ3 ORF expression vector (OriGene, USA) after mutating the desired 
nucleotide, immunoprecipitated with anti-myc antibodies slurry, then HDAC 1 and 2 
probed separately. Real-time PCR to quantify CASP4 was then performed. TSHZ3 is 
known to form a silencing complex with other partners (SET, FE65 and HDACs) to 
silence CASP4 expression (Kajiwara et al., 2009). However, the outcome of these 
experiments were not convincing on implicating TSHZ3 as the cause for the observed 
phenotype. We found that both the wild type and the mutant TSHZ3 proteins bound 
HDACs 1 and 2 similarly (Figure 32), and the level of CASP4 expression was not 
significantly changed in the patients mRNA compared to multiple normal controls 
(Figure 33). We also examined the availability of other human or animal models with 
mutations in TSHZ3 gene and in which the same phenotypes. We looked at 
publically and some privately available data and identified another patient suffering 
from microcephaly, moderate ID, global developmental delay and other phenotypes 
with a compound heterozygous variants (c.3122A>C, p.Tyr1041Ser and c.1333G>A, 
p.Val445Met) in TSHZ3. The allelic frequencies of these variants were 0.00008 and 
0.0019836, respectively. In addition, two more patients had compound heterozygous 




dysmorphic features, however, one of them had normal OFCs, while the other had +2 
SD circumference (macrocephaly). Unfortunately, we were unable to carry out 
detailed analysis of these patients at this stage. Attempts to identify individuals with 
variants in this gene will continue. 
 TSHZ3 protein is highly expressed in the cerebral cortex, localizing in the 
nuclei (www.proteinatlas.org). TSHZ3 proteins have been found to localize in the 
cell bodies and the growth cones of the primary neuronal cultures in rats cortex 
(Kajiwara et al., 2009). Likewise, STIL gene (reported in microcephalic patients) was 
found to be expressed in the perinuclear region, assuming a role in the mitotic entry 
(Kaindl et al., 2010). TSHZ3 encodes a transcription factor that regulates smooth 
muscles differentiation. Mutant TSHZ3 in mice caused hydronephrosis and they 
were unable to actively propel urine down to the bladder (Caubit et al., 2008). Not 
only did mice develop kidney problems, but they also displayed learning difficulties. 
 TSHZ3 also regulates the development of neurons in respiratory rhythm and 
airflow. Mice deficient for this protein failed to breathe and died soon after birth 
(Caubit et al., 2010). However, these modules (knockouts) fully inactivate TSHZ3, 
which might not be the case of the missense variant which we have identified, 
probably these missense variants alter some of the TSHZ3 functions which we have 
not yet identified.  
  Candidate-gene criteria scoring system had shown that reported 
microdeletions or duplications that harbor the gene of interest is considered a 
weighted evidence for its candidacy (Farwell Hagman et al., 2017). In line with that, 
Caubit X and his colleagues identified TSHZ3 to be the smallest region of overlapped 




spanning a number of genes in patients suffering from ID, developmental delays, 
microcephaly, autistic features and other anomalies (Malan et al., 2009), (Kulharya, 
Michaelis, Norris, Taylor, & Garcia-Heras, 1998), (Gana et al., 2012), (Castillo et al., 
2014), (Chowdhury et al., 2014). All deletions were heterozygous, suggesting 
possible haploinsufficiency of TSHZ3 to cause the neurocognitive impairments 
(Caubit et al., 2016).  
Morpholino knockdowns, on the other hand, showed a dose-dependent loss of 
the viscerocranium and the neural-crest derived cartilages of the anterior 
neurocranium (Melvin et al., 2013). 
The identified variant in the current study had a very low allelic frequency 
(0.00019) in ExAC database, with only one individual carrying the same variant but 
in a heterozygous state. The same variant did not exist in the exome variant server 
and there was a single probably damaging missense variant in TSHZ3 gene in a 
homozygous state in an African American individual out of 6447. Moreover, the 
variant was absent in the Allele frequency database of Arab disease mutations 
(GalaxC). Additionally, the variant was not available in the GME variome 
sequencing project (http://www.igm.ucsd.edu/gme/). 
The second strong candidate gene in family 3 was LRRK2, as noticed from 
Table 3 that this gene lay within the longest homozygous stretch (27.8 Mbps).  It is 
expressed in most cells, indicating its involvement in basic cellular functions 
(Alegre-Abarrategui et al., 2009). The identified variant (c.4325_4327delCTT) leads 
to a deletion of alanine amino acid at position 1442. LRRK2 stands for Leucine Rich 
Repeat Kinase 2, it encodes a protein of 2527 amino acids with multiple essential 




domain, a MLK-like domain, and a WD40 domain (www.uniprot.org). A reported 
mutation (Arg1441Cys), which is very close to ours, impaired the autophagic balance 
by accumulating multi-vesicular bodies and autophagic vacuoles in several unrelated 
patients affected by Parkinson disease (Wszolek et al., 1995). This variant was 
located in the Ras of complex (ROC) domain with GTPase function, hence, it 
appeared to enhance the kinase activity rather than the localization of LRRK2 protein 
(West et al., 2005). In a crystallographic study performed on the following variants; 
(p.Arg1441Cys, p.Arg1441Gly, and p.Arg1441His) identified in Parkinson patients, 
the variants were located at the interface of two monomers crucial for the (ROC) 
domain stability. Intriguingly, another substitution (p.Ala1442Pro), occurring at the 
exact locus of our identified variant was also detected and it was suggested to disrupt 
the region in a similar mechanism as the variants at position 1441 did (Deng et al., 
2008).  
The identified variant in our study occurring at position 1442 could at least 
similarly affect the stability of the ROC domain. In addition, the variant was not 
found in the exome variant server, 1000 genome project, ExAC, GalaxC, GME and it 
was predicted to be disease causing by Mutation Taster and deleterious of a high 
score (-10.546), cut off value (-2.5) by Provean software (www.provean.jcvi.org). 
LRRK2 gene is located within the biggest homozygous stretch (27.8 Mbs), and it is 
highly expressed in the cerebellum and cerebral cortex. 
Our main conclusion from these results is that TSHZ3 and the remaining 
segregating genes cannot be excluded as a potential cause of the phenotype in family 




convincing assays that will address the issue and can effectively draw a conclusion 
about the association of the identified gene (s) in the studied families. 
Family 4 has four children; two of them are affected with ID, dysmorphic 
features and anorectal anomalies, and two unaffected children born to a 
consanguineous family (Figure 35A). Large homozygous intervals were mapped to 
chromosomes 4, 5, 7, 8, 10, 12, 13, 14, 15, 16 and 18. The distance of the 
homozygous regions harboring the candidate genes ranged from 10-18.5 Mbs (Figure 
35B). The candidate genes that resulted from WES analysis were KMT2C, PDE1C, 
CRTAC1, GIMAP2, NRXN3, and DSC3. Segregation analysis for all the candidate 
genes was performed on all the family members by Sanger sequencing. The results 
of sequencing identified a non-synonymous variant (c.1798G>A, p.Glu600Lys) in 
CRTAC1 gene and it was the only gene segregating in the family (Figure 36). Hence, 
further analyses were ceased on the remaining non-segregating genes. WES and 
Sanger sequencing confirmed the variant in CRTAC1 gene. The change was predicted 
to be disease-causing/deleterious by Mutation Taster/SIFT softwares, as the nature of 
the change, from acidic to basic amino acid affects. The same variant did not exist in 
the exome variant server; however, only one probably damaging variant in the same 
gene existed in 3 individuals in a homozygous state out of 6216 European 
Americans. However, the same variant existed in one South Asian individual in a 
homozygous state with allelic frequency of 0.0001818 
(www.exac.broadinstitute.org). 
 CRTAC1 gene encodes cartilage acidic protein 1 which is an extracellular 
protein found in deep articular cartilage. It is a marker used to differentiate 




human marker gene for cultured chondrocytes. The encoded protein is made up of 
661 amino acids, with an N-terminal signal of 27 amino acids and a c-terminal EGF-
like domain (Winter et al., 2003). Besides its expression in chondrocytes, a smaller 
transcript was shown to be as well expressed in brain and lung (Steck et al., 2001b). 
The identified variant (p.Glu600Lys) is located within the EGF-like domain between 
amino acid 559-605. It derived its name from epidermal growth factor which was 
first identified in, containing 30-40 amino acids in the extracellular domain of the 
membrane bound proteins or in secreted proteins, it is an evolutionary conserved 
sequence and it contributes significantly to the function of the protein. 
 CRTAC1 gene is located at chromosome 10, cytogenic band 22q. Splice 
variants generate two forms of the protein, CRTAC1-A and CRTAC1-B, both are 
expressed in brain, such that isoform A lacks intron 14, exon 15 and intron 15, 
whereas isoform B lacks intron 14 (Steck et al., 2007). Interestingly, the identified 
variant is located in exon 14 which is highly conserved in all splice variants. 
Furthermore, CRTAC1 protein was found to be highly conserved in vertebrates, and 
more specifically the EGF-like Ca-binding domain where our variant is located 
(Figure 37) and this binding is crucial for protein interactions. Moreover, several 
human diseases have been associated with EGF-like domain containing proteins, 
such as Marfan syndrome (Downing et al., 1996). 
 CRTAC1 protein binds to NgR1, a receptor of myelin-derived axon growth 
inhibitors. The latter is responsible for the inhibition of neural regeneration in adults. 
CRTAC1 suppresses NgR1. It was suggested that this suppression is crucial for the 




 Moreover, CRTAC1 protein is experimentally determined to interact with 
MAPRE2 (Microtubule-Associated Protein, RP/EB family) (www.string-db.org). 
MAPRE2 has been associated with several patients suffering from circumferential 
skin creases, ID, cleft palate, short stature, and dysmorphic features (MIM 616734) 
(Isrie et al., 2015). 
 To prove the causation of this variant to the phenotypes in family 4, designed 
experiments to study the effect should be conducted from the previously shown 
acquired data. It would be valuable for example, to test the binding ability of the 
mutant CRTAC1 to calcium ions compared to normal controls. On the other hand, 
clinical validity of the gene can be assessed with weighted evidences, and that could 
be achieved by finding more reported cases from unrelated families carrying variants 
in the same gene. Such that if three reported pathogenic variants were recovered in 
unrelated individuals, the gene could be categorized as ‘limited’. In addition, the 
availability of animal models presented with comparable phenotypes could assist in 
providing more evidence. In addition, in vitro studies to demonstrate functional 
disruption compliant with the disease, and which can be rescued in a cellular assay 
give stronger evidence than model system does (Farwell Hagman et al., 2017). 
 In conclusion, candidate genes are reported when significant evidence is 
provided. If the alteration in genes did not provide enough evidence to support its 
clinical implication, it is often categorized under ‘uncharacterized genes with an 
insufficient level of evidence’. These types of genes require corroborating evidence 
in order to confirm their association with the disease. Moreover, showing that the 
gene product interacts with another protein that was implicated in the same disease 




 Despite the fact that a large proportion of human diseases are caused by 
mutations in the non-coding regions, we focused here on sequencing the 1-2% of the 
human genome in order to identify causal genes. By this approach we could avoid 
complexities and higher costs of WGS. However, drop in the cost and ease of 
interpreting WGS huge data could replace WES in future. The human genome harbor 
around 165 homozygous truncating variants (Robinson, Krawitz, & Mundlos, 2011), 
which means that variants that appear to be pathogenic, do not necessarily relate to 
the studied phenotype. Hence, bioinformatics assists in prioritizing such variants 
referring to multiple tools and databases. During WES filtration, variants that are 
included with the candidate genes due to certain criteria but do not relate to the 
phenotype are considered false positive. On the other hand, some genes are poorly 
covered by WES, leading to false negative results. Additionally, some variants could 
be missed due to their distant enhancer regions. 
In many consultation clinics, many diseases such as ID cannot be diagnosed 
whether they are caused by autosomal recessive, multifactorial, environmental or by 
de novo mutations. In such genetically heterogeneous diseases, de novo mutations 
should not be under-appreciated. 
Researchers could never be entirely certain the candidate gene is truly the 
causative gene unless the same gene is identified in other unrelated families with 
comparable phenotypes. Besides, the proof of a candidate gene comes from 
experimental evidence as well as clinical and statistical data. Nowadays, the proof 
requirements needed for new genes discovery are high, in order to meet the high 
standards in human genomics (S. Richards et al., 2015). Sample size is as important 




thus, collaboration between geneticists, clinicians and scientists would be of great 
importance in this case. Moreover, referring to genomic repositories could 







Chapter 5: Conclusions 
Genetic disorders are caused by mutations in the human DNA. These 
mutations vary from single base substitutions to gross deletions in one or more 
chromosomes. Some disorders occur due to mutations in one gene and they are 
therefore, referred to as “monogenic” or single gene disorders. Autosomal recessive 
disorders are single gene disorders where deleterious mutations are passed from both 
parents to offspring and for the phenotype to appear, both alleles must be mutated. 
When parents are carriers, then there is a 25% chance to have an affected child for 
each pregnancy who inherited both affected alleles from their parents. In the vast 
majority of cases, carriers of the defective alleles are unaware of their status, and if 
both parents were carriers, they are at high risk (25%) of passing the disease to their 
children. The probability of both parents being carriers is significantly increased in 
consanguineous marriages, because they inherit some identical genetic material from 
a common ancestor. It is worth noting that the rates of consanguinity in most Arab 
countries including the UAE is very high reaching 40-50% of all marriages. In fact in 
the UAE, consanguinity exceeds 50% of all marriages, with most of those marriages 
being first cousin unions. This clearly contributes to the increased rate of birth 
defects in the country as well as other Arab and Middle Eastern populations. 
Therefore, the major aim of this study was to elucidate the molecular and cellular 
basis of several families with single gene disorders. 
Robust genomic tools have significantly accelerated the discovery of 
defective genes underlying monogenic disorders. The approach I have employed in 
this project to identify novel disease genes is combining whole exome sequencing 




genome SNP genotyping. The combination of mapping the homozygous regions 
inherited in the families, which are most likely harboring the mutated gene, as well 
as exploiting whole exome sequencing to identify pathogenic variants in the protein 
coding regions and their flanking intronic regions, is an approach which has been 
proved in recent years to be effective, and which enabled us to identify some 
candidate genes for the phenotypes described in the affected families. Furthermore, 
attaining experimental evidence to support pathogenicity and establish the cellular 
mechanisms of diseases are very important approaches for accurate diagnosis as well 
as prevention and management of diseases.  
In family one (Section 3.1), I identified two compound heterozygous variants 
in MPDZ gene detected by whole-exome sequencing and confirmed by Sanger 
sequencing in the affected child. Additional experimental data suggested that these 
variants are the most likely cause of congenital hydrocephalus in the affected child. 
The deleterious effect of the first variant (c.394G>A, p.Gly132Ser) has been inferred 
by NMD mechanism of mRNA to affect a splice-site region of one allele as shown 
by sequencing the cDNA from the patient, and by constructing a mini-gene plasmid 
with the same variant; I was able to demonstrate exon skipping in MPDZ gene 
comparing it to a plasmid harboring the wild-type part of the gene. In addition, 
bioinformatics and protein modeling data provided evidence on the pathogenicity of 
the missense variant (c.1744C>G, p.Leu582Val). In addition, the clinical 
presentation was consistent with CH and we therefore concluded that the phenotype 
in the affected child was most likely caused by the identified compound 
heterozygous variants in the MPDZ gene. Our findings on this family are in line with 
other reported in a small number of patients with CH having mutations in MPDZ 




Saudi Arabia and Senegal as presented in Table 6. Therefore, our findings further 
confirm the involvement of this gene in CH and its functional importance in cell-cell 
adhesion and permeability in humans, and the fact that the protein is expressed in 
brain and neuronal tissues. 
In family 2 (Section 3.2), we identified a novel disease-causing XYLT1 
variant (c.2169dupA, p.(Val724Serfs*10)) and presented data to suggest that 
retention of XYLT1 mutant proteins in the ER as the underlying mechanism for 
decreased XYLT1 activity of several reported mutations in this gene. This was based 
on generating these mutants (c.1441C>T, p.Arg481Trp and c.1792C>T, 
p.Arg598Cys and c.2169dupA, p.Val724Serfz*10) in XYLT1 cDNA cloned into a 
mammalian expression vector. Hence, decrease in mature GAGs could possibly be 
the underlying disease mechanism for DBQD II, and this approach might be 
considered a functional test in newly diagnosed patients associated with missense 
mutations of unknown significance, to confirm pathogenicity. 
In families 3 and 4, affected children suffered from monogenic ID 
syndromes. The approach we employed was combining two major technologies to 
identify the candidate genes; homozygosity mapping by obtaining genome-wide SNP 
array of all family members and next generation sequencing of all the exons and 
splice sites of most known genes within the genomes of the affected individuals. In 
family 3 (Section 3.3.1), two siblings suffering from ID, microcephaly and muscle 
hypotonia were analyzed, and I was able to identify six candidate genes based on the 
pipeline mentioned in section 1.4.4.5. However, it is not uncommon that new 
candidate genes could not be easily and successfully verified experimentally. In this 




the disease. We therefore submitted our data to common databases to get connected 
with scientists with patients exhibiting variants of unknown significance in the same 
genes. Furthermore, combining expression analyses and protein interactions links the 
prediction of candidate genes to the diseases. Moreover, designing future 
experimental assays that could show true gene association with the given diseases 
plays a significant role in gene discovery. 
Some functional assays were performed on patients of family 3 in order to 
correlate the candidate gene (TSHZ3) with the phenotypes. It was hypothesized that 
the mutant TSHZ3 protein will not be able to cooperate with FE65, HDAC1 and 
HDAC2, hence to the promoter region of CASP4 gene. This in turn, would lead to 
increased expression of CASP4. Accordingly, patient’s cDNA was quantified by 
real-time PCR, and compared with multiple healthy controls to prove whether the 
identified variant could alter CASP4 expression. In addition, binding assay was 
performed on the mutant TSHZ3 overexpressed protein versus the wild-type to 
assess their interaction with the silencing complex using WB technique. 
Unfortunately, our experiment data on this family are still not enough to claim a 
definitive conclusion on the possible involvement of TSHZ3 gene in the disease. We 
will therefore, seek additional evidences which could include recruitment of other 
patients, animal models or other functional assays. Similarly, the identified candidate 
gene (CRTAC1) in family 4, with two siblings suffering from ID, dysmorphic 
features and anorectal anomalies, showed high preference amongst the other genes. 
Interestingly, CRTAC1 was the only gene segregating with the phenotype among the 
family members. Besides, bioinformatics analyses predicted the variant (c.1798G>A, 
p.Glu600Lys) to be pathogenic; as it was located within the EGF-like domain of the 




These initial studies demonstrated favorable argumentation to look deeply 
into the relation between the identified variants and the studied diseases. The main 
outcomes of such experiments should explain the severity of the variants on the 
patients, supported by relevant animal model or the presence of multiple affected 
unrelated individuals carrying pathogenic variants on the same genes. 
5.1 Potential Implications and Limitations of the Study 
Despite recent advances made in the genomic and bioinformatics tools, 
discovering new genes underlying inherited disorders, such as monogenic disorders 
has proven to be challenging in significant number of cases. Powerful approaches are 
needed to link newly discovered genes to the current diseases. Next generation 
sequencing, SNP genotyping and CGH array, in addition to computational and 
bioinformatics tools have already been used in this study, followed by experimental 
studies, to functionally validate their association with the diseases. While not all the 
candidate genes have proved their implication in the studied patients, it is expected 
that there will be many to fulfill, by implementing more experiments.   
In this dissertation, I studied four families with presumed autosomal recessive 
single-gene disorders and the findings can be briefly summarized as:  
 Established the association of two MPDZ gene novel variants in the 
pathogenesis of a mild non-progressive communicating congenital 
hydrocephalic patient. 
 Established the causative effect of a novel variant in XYLT1 gene in a patient 




 Established the cellular mechanism and involvement of the ER quality 
control in the pathogenesis of three disease-causing variants in XYLT1.  
 Identified THSZ3 and LRRK2 as possible candidate genes in a family with 
monogeneic intellectual disability characterized by microcephaly, ID and 
muscle hypotonia. 
 Identified CRTAC1 as the candidate gene in a family with monogenic 
intellectual disability characterized by dysmorphic features, ID and anorectal 
anomalies. 
5.2 Future Perspectives 
 In order to evaluate the evidence of the gene variants identified in this study 
whether they exert major effects on the patients or not, we should outline reasons to 
corroborate their candidacy. This could be obtained by executing functional assays to 
include or exclude those genes. 
 Two families (3 and 4) were analyzed by WES and homozygosity mapping 
combined with bioinformatics to assess the discovery of the involved genes. In 
family 3 where the affected children suffered from microcephaly, ID and muscle 
hypotonia, two functional analyses were performed based on postulated hypotheses 
mentioned in previous chapters. However, the performed experiments could not 
prove the effect on the disease mechanism. Nevertheless, while this explains why we 
were not able to prove the candidacy of TSHZ3 gene, it also shows that we were not 
misled by a false-positive variant, given other presented supportive data. In this 




 The highly ranked candidate gene in family 3 was TSHZ3 gene. As the 
variant (p.Lys252Arg) lies within a nuclear localization signal 
(PRRWSKPRKR), we propose studying the localization of the wild/mutant 
TSHZ3 protein in different cell lines. 
 The second strongest candidate gene identified in family 3 was LRRK2. The 
variant (p.Ala1442del) was located in (Ras of Complex) (ROC) domain, 
which acts as a GTPase to regulate protein kinase activity. Protein modeling 
of the mutant LRKK2 can be designed to study its effect on the stability of 
the ROC dimers. 
 As CRTAC1 gene has the only segregating variant with the phenotype in 
family 4. The variant (p.Glu600Lys) is located within the EGF-like domain 
which binds calcium ions crucial for protein interactions, thus, it would be 
valuable for example, to test the binding ability of the mutant CRTAC1 to 
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